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ABSTRACT
Pediatric formulations have received great attention from regulatory agencies in
the United States and Europe. Since solid dosage forms such as tablets and capsules will
not be able to improve pediatric patients’ compliance, customized pediatric formulations
are needed. In response, formulators in the pharmaceutical industry have made significant
effort into developing various pediatric formulations. However, developing satisfactory
pediatric formulations is a process that is guided by case by case basis.
The objective of this current study was to apply the scientific pharmaceutical
technology concepts into developing modern pediatric formulations. We have shown that
the drug delivery design will be affected by the route of administration and by the type of
dosage form utilized. We are hopeful that our approach will serve as a tool to assist
formulations development. Three drug molecules and an anion were utilized in this work
(Chlorpheniramine Maleate, Prednisone, Sulfamerazine, and Iodide ion). Each drug
molecule was utilized according to its physicochemical properties along with the
pediatric patients’ needs. As a result, several pediatric formulations were developed. Here
is the list: taste masked orally disintegrating tablet, taste masked orally disintegrating film,
taste masked mini-tablet, reconstituted nanocrystals and a transdermal microemulsion.
We are hopeful that these dosage forms will serve as good examples for specialized
pediatric formulations and will attract pharmaceutical industry to adapt some these
delivery systems into their development strategy.
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CHAPTER 1.

INTRODUCTION

Due to the lack of pediatric formulations, the regulatory agencies have initiated
continual emphasis on the necessity for developing novel pediatric formulations. In
response, pharmaceutical companies have developed various novel pediatric formulations
some of which have already been launched into the market.
To develop a satisfactory pediatric formulation, an appropriate route of drug
administration is the prerequisite and can be selected from one of the followings: oral,
topical/transdermal, buccal, rectal, nasal, pulmonary, ocular, injectable, etc.1
1.1.

Oral Pediatric Formulation

In general, oral delivery of pediatric drugs is preferred over other delivery routes
since it is convenient, economical, and user-friendly. Based on Strickley and co-workers’
classification,1 pediatric oral formulations were divided into two types: (1) Ready-to-Use
formulations, which do not need manipulation prior to dosing; (2) Manipulation-Required
formulations, which require manipulation under some instructions prior to dosing. In
contrast to regular adult oral formulations such as tablets and capsules, pediatric oral
formulations are likely to contain some specific features to achieve good patient
compliance for pediatrics. In response, several customized oral pediatric formulations
were by far developed.
1.1.1. Orally disintegrating tablets (ODTs)
ODTs are designed to disintegrate in the oral cavity instead of the GI tract and
therefore a rapid disintegration, usually in less than a minute, is necessitated under the
exposure of saliva. Previous studies indicated that there has been a remarkable growth of
ODT demand since the majority of patients preferred (more than 85% of patients) and
would purchase ODTs (70% of patients) rather than other regular tablet formulations.2
ODTs can be produced by different techniques, which include freeze-drying process,
molding/cotton-candy process, and compaction process.3 To scale-up ODT preparation,
conventional tablet compression method and instrument with some modifications are
applicable.4
Unlike regular tablets needed to be swallowed integrally, ODTs eliminate the
necessity of tablet swallowing and thus fairly suitable for elder children. It is worth
noting that several ODT products have already been launched to commercial market for
pediatrics such as Prevacid® (lansoprasole), Zofran® (ondansetron), and Clarinex®
RediTabs® (desloratadine).1 In view of challenges of ODT development, one obstacle
attributes to the unpleasant taste of some APIs that is essentially associated to taste
masking. Tablet film-coating is not applicable for ODTs since ODT is disintegrated in the
oral cavity and consequently unpleasant taste of drug is sensed. Coating in the powder
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level is one approach to achieve taste masking for ODTs. Xu and co-workers developed
Famotidine: Eudragit® EPO: colloidal silicon dioxide: polyethylene glycol 400
microspheres using spray-drying technique and then these microspheres are incorporated
into ODTs.5,6 Conversely, Khan and co-workers prepared ondansetron HCl in
Eudragit® EPO complex using precipitation method, followed by formulating ODTs.
Moreover, if drug content is relatively low in ODTs (less than 20 mg), the addition of
flavors and sweeteners is another feasible approach.1
1.1.2. Film strips/Orally disintegrating films (ODFs)
The first ODF product (Listerine PockerPaks®) was introduced to the market by
Pfizer in 2001 and over time this novel formulation has gained more interest on
popularity. ODF is a film strip which disintegrates rapidly on the tongue without being
chewed or being swallowed. Therefore, ODFs can be administered by pediatric patients
at ease. Two techniques have been developed to prepare ODFs, including casting method
and hot-melt extrusion method. Casting method involves dissolution and/or dispersion of
active pharmaceutical ingredients (APIs) and various excipients in an aqueous medium,
medium casting, and drying. Hot-melt extrusion method, as the relatively new method,
includes extrusion of melted drug and/or polymers’ complex, casting, cooling, and drying.
In order to develop a satisfactory ODF, various excipients are desirable to obtain
acceptable performance such as robustness, content uniformity, taste masking, rapid
disintegration, appearance, etc.7 Film-forming polymer is the primary component of ODF
and play a critical role in film’s mechanical properties. A number of polymers were
utilized individually or in a combination as the backbone of film strips and these
polymers include modified starch (maltrodextrin),8,9 hypromellose,10 andpyrrolidone.11 In
addition, a balance of plasticizer and surfactant in film’s formula is pursued to exhibit
good spreadability and elasticity properties. Taste masking should be reached if APIs in
the ODF are unpleasant. The addition of taste masking agents is the most prevalent way
to attenuate the undesirable taste. On the other hand, the method of coating in the powder
level may be employed for the purpose of taste masking since microparticles could be
incorporated in film matrix successfully.12
1.1.3. Mini-tablets
Apart from ODT and ODF, mini-tablet is another option to achieve formulation
swallowability for pediatric patients. Mini-tablet is defined as a tablet with a diameter
less than 3 mm.13 As a replacement of regular tablets, mini-tablets can be swallowed by
children less than 10 years old at their ease.14
There is a potential for mini-tablets to be applied widely as a pediatric
formulation due to (1) its unique advantages such as regular shape, good appearance,
acceptable mechanical properties, and uniform content; (2) the feasibility of mini-tablets
(1 mm and 2 mm in diameter) manufacturing using regular tablet compression machine.15
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In addition, mini-tablets were utilized in other drug route of administration instead
of oral. For example, some researchers applied coated mini-tablet as an ophthalmic insert
for drug control release in eyes.16
1.1.4. Nanocrystals (constituted to a suspension)
Powder (granule) is a type of “Manipulation-required formulation” and has been
utilized very commonly as a pediatric formulation. Prior to the application, this
formulation is necessary to be constituted to a suspension formulation. Apart from API
powder, other excipients can also be added into the powder blend, including flavor agents,
color agents, sweeterners, dispersing agents, buffering agents, preservatives, viscosity
modifiers, etc.1
In contrast to regular powder in micron level, nanoparticle has an increase of
dissolution rate and saturated solubility, especially for poorly soluble APIs, which may
result in higher oral bioavailability. Moreover, nanoparticles are easier to adhere to GI
membrane and consequently enhance oral bioavailability further.17
Currently there are several techniques for yielding nanosuspensions. In general,
these methods can be divided into two main categories: “bottom-up” technology and
“top-down” technology. The “bottom-up” technology basically is those methods via
recrystallizing nanocrystals from solution. Due to inherited limitations of “bottom-up”
technology such as wide variation in particle size distribution, solid state transformation
(unstability), and scale-up difficulty, this technology is not widely applied.18 On the other
hand, the “top-down” technology such as wet bead milling and high pressure
homogenization which involves methods about reducing particle size from micron range
is more popular. Wet bead milling involves the milling process of powders in aqueous
medium by colliding with glass/pearl beads. Conversely, high pressure homogenization is
a relatively new technology and nanoparticles are achieved using more sophisticated
equipments. One example is the microfluidizer, where particles were milled by two highvelocity jet streams. The other most-common equipment is piston-gap homogenisers. In
this equipment, a drug solution is pushed through a gap by the aid of large force applied
by a piston, followed by the boiling of liquid droplets. Sequentially these gas bubbles
fracture with the formation of nanocrystals.19
1.2.

Transdermal Formulations

When oral or parental route of administration is inapplicable or encountered with
insufficient patient compliance, alternative routes such as transdermal delivery is pursued
with good pediatric patient compliance.
Transdermal delivery has been utilized for several decades and considered as a
non-invasive route of administration. Although, transdermal delivery is utilized in several
clinical situations, the main challenge for this delivery route has always been the drug
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dose and the skin permeability since skin function as a barrier to prevent external
invasions. Nanotechnology has been utilized in transdermal drug delivery to improve
permeation; and microemulsion is considered the second most popular colloidal system
which has been used for dermal applications.20
Microemulsion is a multicomponent system composed of water, oil, surfactant,
and cosurfactant.21 Here, we mention several advantages of microemulsions: First, the
procedures for preparing microemulsions are simple, inexpensive, and rapid. Second,
microemulsions have shown to enhance the permeability of hydrophobic and hydrophilic
compounds,22 either by decreasing the skin resistance or by increasing the concentration
gradient of the drug diffusion.23 In addition, the nano-size droplets of microemulsion are
more likely to adhere to the skin surface and penetrate into the skin.22 In addition,
microemulsions as compared to regular emulsions (microns size), are thermodynamically
stable during storage, packaging, and transportation due to the lack of fixed curvature and
the low interfacial tension.
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CHAPTER 2. EVALUATION OF CHLORPHENIRAMINE MALEATE
MICROPARTICLES IN ORALLY DISINTEGRATING FILM AND ORALLY
DISINTEGRATING TABLET FOR PEDIATRICS﹡
2.1.

Introduction

In recent years, pediatric formulations have gained more attention from private
and governmental institutes. Although there were many governmental incentives offered
to pharmaceutical companies to design and improve new pediatric formulations,
developing a satisfactory pediatric formulation is still a challenging task for many reasons:
(1) Overwhelming majority of active pharmaceutical compounds are poorly soluble
and/or poorly absorbable which cause low bioavailability; (2) Some pediatric
formulations such as powders or granules have tremendous dose strength fluctuations
while dosing; (3) Swallowing appropriateness may not be achieved easily for children
less than 10 years of age; (4) Many active pharmaceutical compounds or excipients have
unpleasant taste.1 Despite critical issues such as low solubility/stability and dose strength
fluctuations, swallowing inappropriateness and unpleasant taste are the two most critical
obstacles that cause very low patient compliance, specifically for the pediatric patients.
Since a large number of active pharmaceutical ingredients have unpleasant taste,
various methods have been developed by formulation scientists to attenuate the
undesirable taste. It has been reported that appropriate flavors, sweeteners, and amino
acids were simply incorporated into the formulations for the purpose of taste masking.24
Lipophilic vehicles were typically used to prevent the contact between bitter taste drug
molecules with taste buds on the tongue by way of inhibiting the sense of bitterness.24
Complexing agents such as cyclodextrin were used to bind bitter taste drug molecules
inside its hydrophobic cavity to mask bitterness.25,26,27 Taste masking was also achieved
via binding of drug molecules into ion-exchange resins.24,28 Apart from all these above
mentioned taste-masking techniques, the utilization of a pH-dependent polymer as a
coating material to avoid the contact between taste buds on the tongue with bitter tasting
drugs is a feasible and economic approach. Selectively, Eudragit® EPO, a pH-dependent
copolymer, is insoluble in saliva (pH 6.8) but dissolves rapidly in gastric fluid (pH 1.5-2).
Therefore, film coating with Eudragit® EPO can inhibit the release of drug from a tablet
in the saliva and mask the bitter taste.29 This polymer was also used as a moisture
protectant during tablet coating.29 Additionally, Eudragit® EPO is suitable for powder
coating. In contrast to other techniques of making microparticles, spray drying technique
has a continuous, automated and quick process for producing products and therefore can
be scaled up for industrial uses. In the past, API-Eudragit® EPO has been utilized to
synthesize microparticles for masking the unpleasant taste of drug powders and loaded

﹡: Adapted with permission. Lou H, Liu M, Qu W, Hu Z, Brunson E, Johnson J,
Almoazen H. Evaluation of chlorpheniramine maleate microparticles in orally
disintegrating film and orally disintegrating tablet for pediatrics. Drug Dev Ind Pharm. In
Press.
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into oral dosage forms.5,6 In this study, we selected orally disintegrating tablet (ODT)
because ODT are different from traditional tablets since they are designed to disintegrate
in the oral cavity instead of the GI tract. Therefore, pediatric patients can avoid
swallowing a whole tablet and consequently enhance patient compliance. However, some
pre-school children still have difficulty grasping skills of administering ODT because
they cannot follow instructions such as “no swallowing” or “no chewing” properly. This
makes orally disintegrating film (ODF) a viable option. ODF is a film strip which
disintegrates rapidly on the tongue without being chewed or being swallowed. In contrast
to ODT, ODF can be administered to pediatric patients with more ease since it is likely
that users are already familiar with the use of this category of products by using breathfreshening strips.7 It is noted that the manufacturing process of ODT is much simpler and
more cost-efficient as compared to that of ODF. To prepare ODF, either solvent casting
method with solvent involvement or hot-melt extrusion method with external heat input is
needed.7 In contrast, ODT can be directly compressed from powder blends without
solvent or heat. Here we claim that both of these formulations are suitable for pediatric
populations with some inherited advantages and disadvantages.
In this study, Chlorpheniramine Maleate was chosen as the model drug since it
has been widely used as an antihistamine drug for pediatric patients. This drug is highly
water soluble and has acceptable bioavailability.30 However, it is still difficult to develop
satisfactory pediatric formulations such as ODT and ODF without masking the bitter taste
of Chlorpheniramine Maleate.
The objective of this study was to develop satisfactory ODT and ODF
formulations that could mask the taste of Chlorpheniramine Maleate. For this purpose,
API-Eudragit® EPO microparticles were synthesized using the spray drying technique.
The formulation of microparticles was optimized depending on two criteria (relatively
high encapsulation efficiency and low drug release rate). Furthermore, although the
feasibility of compressing microparticles with other excipients into ODT has been
reported by others,5,6 incorporating microparticles into ODF has not been investigated. In
this study, we evaluated the feasibility of microparticle incorporation into both ODT and
ODF formulations.
2.2.

Experimental Procedures

2.2.1. Materials
Polyvinyl alcohol and Tween 20 were purchased from Sigma Aldrich (MO, USA).
Chlorpheniramine Maleate was purchased from Spectrum chemical (NJ, USA). Glycerin
was purchased from Fisher Scientific (MA, USA). Eudragit® EPO was kindly donated
by Evonik (NJ, USA). Spray-dried Mannitol was kindly donated by SPI Polyols Pharma
(DE, USA). Lycoat® RS720 was kindly donated by Roquette (IL, USA). Croscarmellose
sodium was kindly donated by FMC Biopolymer (PA, USA). Magnesium Stearate was
kindly donated by Mallinckrodt (MO, USA).
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2.2.2. Preparation of microparticles
API-Eudragit® EPO microparticles were prepared using the spray drying
procedure conducted by Mohanan et al. with minor modification.31 Briefly, 250 mg of
Chlorpheniramine Maleate were weighed and dissolved in 5 mL of distilled water
(aqueous phase). Preset amount of Eudragit® EPO was weighed and dissolved in preset
volume of dichloromethane (organic phase). The above two phases were mixed by
manual shaking and emulsified under ultrasonication for 1 minute (QSonica LLC, CT,
USA). Sequentially the obtained w/o emulsion was immediately spray dried with a mini
spray dryer B-290 (Buchi, Switzerland). Spray drying parameters were set accordingly:
aspirator 100%, pump speed 25%, inlet temperature 50 °C, and pre-set compressed gas
flow (indicated by the rotameter Q-flow). Q-flow was applied to disperse solution into
fine liquid droplets at the tip of two-fluid nozzle. Values of the weight ratio of Eudragit®
EPO to drug, the volume ratio of dichloromethane to water, and gas flow (Q-flow) were
selected as depicted in Table 2-1. At the end of spray drying, microparticles were
collected, rinsed with 1% PVA solution, and then dried at room temperature under
vacuum for 24 hours. All harvested dry microparticles were kept at 4 °C in isolated vials
for further use.
2.2.3. Design of experiments
Physicochemical properties of microparticles are influenced by formula
composition and by process variables. To optimize the microparticle formulations
properties, an orthogonal experimental mathematical design L9 (33) was conducted as
shown in Table 2-1.
The weight ratio of Eudragit® EPO to Chlorpheniramine Maleate was defined by
the independent variable (X1), the volume ratio of dichloromethane to water was defined
by the independent variable (X2), and Q-flow (in millimeter) was defined as the
independent variable (X3). Three levels were selected for each independent variable.
Each experiment for the same level was duplicated. Drug encapsulation efficiency and
percentage of drug released at 1 h, 2 h, 3 h, 4 h, 8 h, 12 h, and 24 h were selected as the
key responses. Polynomial equations including linear model Equation 2-1 and quadratic
model Equation 2-2 were utilized to fit the observed results using SAS software (SAS
institute INC, NC, USA). The best-fit model was selected based on the multiple
correlation coefficient (R2), coefficient of variation (CV), adjusted multiple correlation
coefficient (adjusted R2), and multi co-linearity of predictor variables. Bias was checked
by comparing predicted and observed responses.
Y=k+aX1+bX2+cX3
Y=k+aX1+bX2+cX3+dX1X2+eX1X3+fX2X3+gX12+hX22+iX32
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(Eq. 2-1)
(Eq. 2-2)

Table 2-1.
Experiment formulations and the levels of variables according to an
orthogonal experimental design L9 (33).
Formulation
1
2
3
4
5
6
7
8
9

Variables/Levels
X2
3
5
7
3
5
7
3
5
7

X1
5
5
5
7.5
7.5
7.5
10
10
10

X3
30
37.5
45
37.5
45
30
45
30
37.5

X1: The weight ratio of Eudragit® EPO to drug while keeping drug amount constant;
X2: The volume ratio of dichloromethane to water while keeping the volume of water
constant;
X3: Q-flow (mm).
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2.2.4. Drug encapsulation efficiency
Dry microparticles (12.5 mg) were accurately weighed and dissolved in 25 mL of
80% acetonitrile with aid of sonication. The solution was filtered through a 0.22 µm
micro-porous membrane filter. Drug concentration was determined at 262 nm using a UV
spectrometer (PerkinElmer, MA, USA). This experiment was repeated in three replicates.
The drug encapsulation efficiency (%) was calculated according to Equation 2-3.
Actual drug loading

Drug encapsulation efficiency (%)=Theoretical

drug loading

×100

(Eq. 2-3)

2.2.5. In vitro release testes
Dry microparticles (150 mg) were weighed and transferred into a dissolution
basket wrapped with a 0.45 µm micro-porous membrane filter. The modified basket
loaded with sample was suspended in 50 mL of simulated saliva (pH=6.8) under constant
mild mechanical shaking at 37 °C. One milliliter was withdrawn at predetermined time
points (1 h, 2 h, 3 h, 4 h, 8 h, 12 h, and 24 h), and an equal volume of fresh simulated
saliva was replaced after each sampling point. Each retrieved sample was filtered through
a 0.22 µm micro-porous membrane filter, and then was analyzed by UV
spectrophotometer at 262 nm after appropriate dilution.
2.2.6. Checkpoint analysis
Three variable checkpoints at three (X1, X2, X3) levels: (7.5, 5, 37.5),
(8.75, 6, 41.25) and (10, 3, 37.5) were selected to validate and verify the robustness of the
simulation model. Three replicates were performed for each checkpoint. Predicted and
observed drug encapsulation efficiency values were compared using the Student t test. In
addition, by comparing the predicted and observed drug release profiles, the dissolution
profile similarity factor (f2) was calculated according to Equation 2-4 and the application
condition of f2 was specified to this experiment. Predicted and observed release profiles
were considered similar if f2 value was ≥50.
f2=50×log{[1+(1/n)∑𝑛𝑛𝑡𝑡=1(R t − Tt )2]-0.5×100}

(Eq. 2-4)

Where n is the number of time points, Rt is the predicted percentage of drug release at tth
time point, Tt is the mean observed percentage of drug release at tth time point.
2.2.7. Preparation of ODF and ODT
ODF were casted based on the compositions presented in Table 2-2. Briefly,
Lycoat RS720® was dissolved in a solution containing pre-calculated amounts of water,
glycerin and Tween 80 under manual stirring. Microparticles (or Chloropheniramine
Maleate powders) were uniformly dispersed (or dissolved) into the solution. This sample
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Table 2-2.

Composition expressed as (w/w %) for orally disintegrating film and orally disintegrating tablet formulations.
Formulation
Drug only
Microparticles (drug
equivalent of
microparticle)
Lycoate RS 720
Glycerin
Tween 80
Water
Mannitol
Croscarmellose Na
Mg stearate

Film
(Control)
0.75
N/A
(N/A)

Film
(Microparticle)
N/A
10.625
(0.75)

ODT
(Control)
1.55
N/A
(N/A)

ODT
(Microparticle)
N/A
21.9
(1.55)

41.125
5
3.125
50
N/A
N/A
N/A

31.25
5
3.125
50
N/A
N/A
N/A

N/A
N/A
N/A
N/A
93.7
4
0.75

N/A
N/A
N/A
N/A
73.6
4
0.5
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was then allowed to stand until air bubbles dissipated. Thereafter, this obtained viscous
sample was casted on a plastic platform using a 6 mm wet film stainless steel bar
applicator (BYK Inc, CT, USA). The film was dried in a tray oven and was cut into
multiple pieces of 3×3 cm (9 cm2) with the aid of BYK chart paper. ODT were also
prepared based on the compositions presented in Table 2-2. Drug contents as well as
weight of an ODT were pre-calculated based on those of an ODF. All powder ingredients
were blended and compressed into a biconvex tablet with a diameter of 5.56 mm using a
Carver hydraulic press (Carver INC, IN, USA).The compression force was kept constant
at 1.5 kN.
2.2.8. Characterization of ODF
2.2.8.1.

Weight variation and content uniformity

Six pieces of ODF (3×3 cm) were accurately weighed to evaluate weight
variations. For content uniformity evaluation, each film (six replicates) were dissolved in
25 mL of 0.1N HCl solution individually. Consequently, the resulting solutions were
filtered through a 0.22 µm microporous membrane filter. The drug concentration was
determined by UV absorbance at 262 nm.
2.2.8.2.

Tensile strength

Tensile strength (tensile stress at break) of ODF was evaluated using dynamic
mechanical analyzer equipped with a film clamp (TA instrument, DE, USA). A film was
clipped into the clamp with one side fixed and the other side movable. The dimensions of
the film were fed into the analyzer. The preloaded force was kept constant at 0.01 N then
followed by ramping at 0.5 N/min until the film broke. The temperature was maintained
at 25 °C during all the experiments and the average tensile strength was calculated based
on six replicates.
2.2.8.3.

In vitro disintegration

In vitro disintegration testing of ODF was performed using the Pharmacopeia
disintegration apparatus for capsules and tablets (Hanson Research, CA, USA). Each film
strip was cut into an appropriate size (n=3) and then carefully placed at the bottom of a
disintegration basket tube. The system was maintained at 37 °C and simulated saliva was
chosen as the medium. Disintegration time was monitored until the film completely
disintegrated into fine particles.
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2.2.9. Characterization of ODT
2.2.9.1.

Weight variation and content uniformity

Six tablets were weighed to determine average weight variation and content
uniformity, following the same procedures specified in Section 2.2.8.1 (n=6).
2.2.9.2.

Tensile strength

Tablet hardness was measured using a manual tablet testing instrument (Vortex
sales group, NC, USA). Tensile strength was calculated using Equation 2-5:
2∗F

(Eq. 2-5)

d
Tensile strength=π∗D∗H

Where Fd is tablet hardness, D is tablet diameter, and H is tablet central cylinder thickness.
2.2.9.3.

Friability

Friability was performed using a friabilator (Sotax, MA, USA). Twenty tablets of
each formulation were first de-dusted, weighed and mixed with 3 mm glass beads to
make a total weight of around 6 g. Tablets and 3 mm glass beads were placed into the
drum. After 100 revolutions, the tablets were first examined for appearance, and then
weighed. Percent friability was calculated using Equation 2-6.
Percent Friability=
2.2.9.4.

In vitro disintegration

initial weight −final weight
initial weight

×100%

(Eq. 2-6)

The procedure for in-vitro disintegration testing was similar to the one specified
in Section 2.2.8.3. One tablet was cautiously placed in the bottom of a disintegration
basket tube. The average disintegration time was calculated from three replicates.
2.2.10. Drug dissolution from ODF and ODT
Dissolution tests were conducted at two different dissolution setups. Initially, to
evaluate drug dissolution in the oral cavity, the USP basket apparatus (Distek INC, NJ,
USA) was utilized. Three hundred milliliters of simulated saliva (pH=6.8) were
maintained at 37 °C. One film or tablet was placed inside the basket and immersed in the
dissolution medium. The rotation speed of the basket was kept at 50 rpm. The
concentration of Chlorpheniramine Maleate was monitored using an in-line ultraviolet
detector connected with fiber optic cable at 262 nm (pION, MA, USA).
Thereafter, to evaluate drug dissolution in the stomach, the USP paddle apparatus
(Distek INC, NJ, USA) was utilized. Nine hundred milliliters of simulated gastric fluid
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(pH=1.2) were maintained at 37 °C. One film was hanged with a clip or one tablet was
directly loaded into the vessel. The paddle rotation speed was kept at 50 rpm. Drug
concentration was analyzed at 262 nm using the same detector.
2.2.11. Taste masking evaluation
Taste masking evaluation was performed using a single blind study according to a
published design with minor modification.5 The bitterness of two ODFs and two ODTs
were evaluated: ODF (control drug alone), ODF (coated microparticle), ODT (control
drug alone), and ODT (coated microparticle). Ten adult volunteers were involved in this
study. Each individual was asked to place each formulation on his/her tongue for 45
seconds and give a score based on his/her feelings about intensity of the bitterness.
Intensity of bitterness was ranked from four numerals 0 to 3, where 0=no bitterness,
1=slight bitterness, 2=moderate bitterness, and 3=strong bitterness. The average score of
each formulation should be equal to or less than 1 to be considered acceptable for
pediatric applications.
2.3.

Results

2.3.1. Drug encapsulation efficiency
Drug encapsulation efficiency is defined as the ratio of the actual amount of
encapsulated drug to the theoretical amount that was added. This indicator is a vital
criterion which is used to evaluate the quality of microparticles. It has been illustrated
that drug encapsulation efficiency could be significantly influenced by many formulation
and process variables. For example, O’Donnell and McGinity concluded that the
selection of the organic phase and the volume fraction of the organic and aqueous phases
affected the encapsulation efficiency and the microparticle porosity.32 They also pointed
out that the properties and amount of polymers were also influential on the drug
encapsulation efficiency.32 Additionally, the process variables during the spray drying
cycle are considered significant factors. In this study, gas flow (Q-flow) at the nozzle tip
of the spray dryer was selected for further investigation because it controls the dispersion
process of the spray dried solution into fine liquid droplets, thereby possibly affecting the
drying process and drug encapsulation efficiency.
Values of drug encapsulation efficiency for all experimental batches were listed in
Table 2-3. All experimental batches had acceptable encapsulation efficiency values
which ranged from 60% to 90%. After fitting data to both linear and quadratic models,
the best-fit polynomial equation was determined as a modified quadratic model as shown
in Equation 2-7, where the R-square value was 0.98. Analysis of variance (ANOVA)
indicated that drug encapsulation efficiency was significantly influenced by experimental
variables. Moreover, all predictor variables introduced in this equation were significant
variables.
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Table 2-3.

Responses (drug encapsulation efficiency and percentages of drug released) of microparticle formulations.

Formulation
1 replica a
1 replica b
2 replica a
2 replica b
3 replica a
3 replica b
4 replica a
4 replica b
5 replica a
5 replica b
6 replica a
6 replica b
7 replica a
7 replica b
8 replica a
8 replica b
9 replica a
9 replica b

% EE
70.5
70.0
74.3
71.6
62.8
59.8
86.8
87.9
81.0
81.6
73.2
70.0
84.2
84.8
71.1
69.0
69.6
69.8

Y1h
19.6
20.7
19.6
16.7
20.8
26.3
17.5
16.6
12.7
10.9
15.7
13.9
7.0
11.0
13.9
14.0
13.8
12.0

Y2h
29.7
28.5
46.2
38.3
32.7
37.8
23.3
21.1
20.3
18.1
25.6
23.6
12.3
13.3
18.6
20.5
25.0
23.0

Y3h
35.8
34.2
56.7
45.7
41.4
43.2
25.4
24.9
23.7
24.6
27.8
28.9
14.4
14.8
22.7
24.2
31.0
28.4
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Y4h
39.0
40.2
60.5
51.9
53.2
53.5
27.4
27.8
32.4
27.5
29.8
33.9
19.3
17.6
25.4
26.9
33.6
32.7

Y8h
55.2
59.1
80.7
73.2
64.9
62.3
35.8
37.9
42.1
40.3
42.0
45.6
24.8
20.0
35.5
34.3
41.5
41.3

Y12h
69.2
72.3
89.4
87.9
75.2
71.6
42.6
46.3
49.7
50.9
52.3
56.8
30.2
28.9
42.7
40.8
47.3
48.8

Y24h
93.1
89.6
91.0
90.1
87.5
84.6
62.3
67.6
71.2
76.6
70.1
73.5
41.7
40.5
56.0
59.9
64.4
64.1

Drug encapsulation efficiency (%)=-74.50+13.81X1+6.42X2+4.41X3
+0.98X1X2+0.18X1X3-0.48X2X3-0.81X12
(Eq. 2-7)
The influence of the three variables on drug encapsulation efficiency was
schematically represented by three-dimensional surface response plots as seen in
Figure 2-1. It was observed that drug encapsulation efficiency decreased as
dichloromethane content increased. This observation may be related to the change in the
porous nature of microparticle, which was explained by O’Donnell and McGinity.32 In
addition, Q-flow was positively relevant to drug encapsulation efficiency. During the
spray drying process, dichloromethane was evaporated in an extremely short period of
time at a temperature above its boiling point. The hypothetical explanation is that the
higher Q-flow dispersed the solution into finer droplets and then produced smaller
microparticles that resulted in higher drug encapsulation efficiency. This result was also
observed and explained by others where weakly bounded drug molecules on the surface
of microparticles were more easily removed from larger but less dense particles during
the preparation process.33 Finally, the drug encapsulation efficiency was also significantly
influenced by polymer amount; however, as observed in Figure 2-1, this influence was
parabolic and intertwined by interactions between polymer variable and other variables.
2.3.2. In vitro release tests
Percentage of drug release values were listed in Table 2-3. The slowest drug
release percentage was around 40% at 24 h (Formulation 7) and the highest one was
around 90% at 24 h (Formulations 1 and 2). Release profiles for all formulations resulted
in a burst release in the first segment, followed by a zero-order release. This phenomenon
was explained by Freiberg and Zhu who indicated that initial burst release is caused
mainly by molecules extracted from microparticle shells, and the second zero-order
release segment was primarily dependent on molecules diffusing through the matrix.34
Statistical analysis for the polynomial equations was conducted to determine the
relationship between drug release and variables (X1, X2, X3). Percentages of drug
released at predetermined time points were fitted to both linear and quadratic
mathematical equations. It was noted that although the quadratic model provided an
equation with a better R-square value, multicollinearity issue may result in insignificance
and inaccuracy of statistical analysis using this model. Therefore, the linear model was
chosen for drug release simulation. Linear equations of each time point were described in
Table 2-4. Analysis of Variance (ANOVA) of all regression equations indicated drug
release was mainly determined by experimental variable levels. Multiple correlation
coefficients (R2) which were close to 1 indicated that the developed equations in
Table 2-4 had a good fit to accurately describe the drug release data. The content and
composition of polymers are critical for the release of drug from microparticles.35
In our experimental design, the weight ratio of polymer to drug ranged from 5 to
10 and was the most significant factor. The drug release rate decreased remarkably as
polymer (Eudragit® EPO) content increased. Our explanation is that drug molecules are
more difficult to penetrate through the microparticle shell which contains more amounts
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Figure 2-1. Response surface plot which relates drug encapsulation efficiency (%)
as a function.
(a) Top: Weight ratio of polymer to drug and volume ratio of dichloromethane to water
(Q-flow at 37.5 mm);
(b) Middle: Weight ratio of polymer to drug and Q-flow (volume ratio of
dichloromethane to water at 5);
(c) Bottom: volume ratio of dichloromethane to water and Q-flow (weight ratio of
polymer to drug at 7.5).
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Table 2-4.

Optimum regression equations which influenced the percentages of drug released.

Percentage of
Drug Release
Y1h
Y2h
Y3h
Y4h
Y8h
Y12h
Y24h

Intercept
Constant (%)
30.39
47.33
54.93
53.76
89.68
110.92
130.06

Coefficient a
(X1)
-1.73
-3.35
-4.05
-4.76
-6.60
-7.56
-6.98

Coefficient b
(X2)
0.42
1.65
2.13
2.73
2.70
2.60
2.06
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Coefficient c
(X3)
-0.10
-0.13
-0.13
0.09
-0.19
-0.31
-0.45

P-value

R-square

0.001
0.0002
0.0003
<0.0001
<0.0001
<0.0001
<0.0001

0.68
0.74
0.73
0.80
0.82
0.86
0.90

of the polymer and thereby prolonged the release time. Apart from the weight ratio of
polymer to drug, a faster drug release was achieved as the volume ratio of
dichloromethane to water increased. This variable was also noticed to have an influence
on drug release rate by other researchers.36 It is important to note that evaporating a larger
volume of dichloromethane can possibly result in microparticle shell which is less dense
and more porous, thereby results in faster drug release. Additionally, the third variable
(Q-flow) was noticed to have insignificant influence on drug release.
As a result, microparticles coming from Formulation 7 were selected for loading
into ODF and ODT for two primary reasons: (1) drug encapsulation efficiency was
relatively high (around 84%); (2) drug release rate was relatively slow (only around 10%
released within 1 hour and 40% released within 24 hour).
2.3.3. Checkpoint analysis
Three checkpoints (X1, X2, X3) at three variable levels (10, 3, 37.5) (7.5, 5, 37.5),
and (8.75, 6, 41.25) were applied to validate the robustness of the developed models.
Predicted and observed drug encapsulation efficiency values are listed in Table 2-5.The
predicted drug encapsulation efficiency values of these validated points calculated from
Equation 2-7 were not significantly different from the actual measured values(P>0.05,
statistical student t-tests). Predicted and observed drug release profiles were plotted in
Figure 2-2. All similarity factor (f2) values in Table 2-5 were above 50, which suggest
good similarity between predicted and observed release profiles. It is clear from these
results that the values calculated for percentages of drug released according to the
polynomial model can predict the observed drug release profiles. Moreover, these
simulated models could also be utilized to predict drug encapsulation efficiency and drug
release profile for other new untested formulations.
2.3.4. Characterization of ODF and ODT
The ODF and ODT formulations are listed in Table 2-2. The developed ODF
contains Lycoat as a film forming polymer, glycerin as a plasticizer, Tween 80 as a
surfactant, and drug (microparticles). Physicochemical and mechanical characterization
values are listed in Table 2-6. The average weight of ODF control was 87.9±2.4 mg and
the average weight of ODF with microparticle was 86.3±4.0 mg. Thus, this produced
films had similar weights whether drug was dissolved in or microparticles were dispersed
in the casting solvent. Acceptable drug content uniformity was also achieved for both
ODFs. The average drug content was approximately 1.3 mg, which is suitable strength
for prescribed pediatric dose of 1 to 2 mg. The drug content and the weight of an ODT
were aimed to be identical to those of an ODF. Thus, theoretical drug percentage in
powder blends and in tablet weights were pre-matched. Consequently, the obtained data
demonstrated that ODT controls and ODT with microparticle had extremely small weight
variation and uniform drug content which closely matched their theoretical values.
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Table 2-5.
Comparison between the predicted and the actual values for
encapsulation efficiency and f2 similarity factor testing for the three selected
variable levels.
Formulation (X1 X2 X3) (10 3 37.5) (7.5 5 37.5) (8.75 6 41.25)
Predicted EE%
75.1
77.0
72.4
Observed EE%
74.3±1.5
75.9±1.5
73.8±2.2
P-value (EE%)
0.48
0.31
0.40
Similarity factor (f2)
83.8
72.4
76.5
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Figure 2-2. Predicted and observed release profiles of three validated
formulations.
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Table 2-6.

Properties of orally disintegrating films and orally disintegrating tablet formulations.
Formulation
Weight (mg)
Drug content (mg)
Disintegration (S)
Tensile strength (MPa)
Friability

ODF
ODF
ODT
ODT
(Control) (Micropartile) (Control) (Microparticle)
87.9±2.4
86.3±4.0
86.2±2.2
86.1±1.7
1.318±0.040 1.307±0.052 1.315±0.035 1.332±0.0039
35.3±5.1
36.0±3.6
16.3±1.5
23.7±1.5
0.85±0.09
0.51±0.09
0.53±0.06
1.00±0.11
1.3%
0%
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Tensile strength is a vital mechanical property for evaluating the strength and
robustness of ODF and ODT. ODF controls had significantly higher tensile strength than
ODF with microparticles and therefore ODF controls were more robust. One possible
explanation is that microparticles dispersed in the film strips may cause some strength.
Tensile strength of films in this study was relatively lower than films made by other
groups,8,9 both films kept good integrity during preparation, packaging, and storage
conditions. On the other hand, ODT tensile strength is expressed as crushing strength.
Tensile strength of ODT was noted to significantly increase with the addition of
microparticles which may be due to higher elasticity of copolymer Eudragit® EPO.
Disintegration testing demonstrated that both ODF and ODT disintegrated quickly.
Disintegration time between the two ODF formulations was not significantly different
(P>0.05). However, there was a significant difference between ODF and ODT
formulations and between the two ODT formulations (P<0.05). Both ODFs disintegrated
completely within 40 seconds, which is suitable for the orally disintegrating drug delivery
systems. ODT had a relatively shorter disintegration time due to the inclusion of superdisintegrant croscarmellose sodium in the formula. The ODT controls disintegrated
significantly faster than the ODT with microparticles. This result matched their tensile
strength results. ODT with microparticles exhibited comparable results to the ODT which
disintegrated within 10 to 30 seconds and had a tensile strength of 1 MPa.37 Friability
results indicated that ODT with drug microparticles should have adequate robustness
during package, storage, and transportation.
2.3.5. Drug dissolution from ODF and ODT
The taste of solid formulation is relevant to its drug content and its dissolution
rate. In contrast to conventional taste masking techniques such as artificial flavors and
sweeteners, a coating layer applied onto drug powders has been verified as a better
approach to inhibit contact between drug molecules and taste bud sensors.5,6 It has been
reported that a slow drug release for only few minutes at the initial stage could reduce
unpleasant sensations associated with bitter taste of drugs.38 Thus, taste masking of
Chloropheniramine Maleate can be achieved by reducing the initial drug dissolution rate.
Dissolution profiles for controls and for microparticles in ODF and ODT at different
media are presented in Figure 2-3. Both ODF and ODT loaded with microparticles,
dissolved very fast (90% of total drug amount within 2 minutes) in simulated gastric fluid
(pH=1.2). Hence, drug release was not hindered by microparticles in simulated gastric
fluid. In contrast, Eudragit® EPO microparticles in either ODF or ODT slowed drug
release (approximate 40% at 5 minute) in simulated saliva (pH=6.8) significantly (P<0.05)
as compared to ODF and ODT controls (more than 90% released at 5 minute). The reason
is that, in simulated saliva, drug molecules in ODF and ODT loaded with microparticles
needed to diffuse out from Eudragit® EPO microparticle shell. Additionally, in simulated
saliva, there was no significant difference for drug release from microparticles in either
ODF or ODT. The initial drug burst release from microparticles was observed in both
formulations. The burst release is a manifestation of two reasons: (1) The drug is
hydrophilic (water soluble); (2) Eudragit® EPO is swellable and water permeable at pH
higher than 5 where the micro-channels that exist within microparticle shells enhance
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Figure 2-3.

Dissolution profiles of Chlorpheniramine Maleate.
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drug diffusion. Drug dissolution in the simulated saliva was noticed to be more rapid
under the experimental conditions listed in Section 2.2.11 as compared to those listed in
Section 2.2.5. Obviously, the dissolution rate was influenced by experimental conditions.
It is well understood that diffusion is the main mechanism of dissolution under the
conditions listed in Section 2.2.5 while convection affected the dissolution listed in
Section 2.2.11. In our study, we selected the conditions listed in Section 2.2.5 rather than
those listed in Section 2.2.11 to evaluate drug release models of microparticles. It is
mainly because relatively more experimental deviations among replicates (within same
formulations) were observed in experiments conducted under the conditions listed in
Section 2.2.11. Consequently, it became apparent that we would have some difficulty in
building a precise model for establishing correlation between the variables and responses
and obtaining optimized microparticle formulations.
2.3.6. Taste masking evaluation
Statistical scores of taste masking evaluations were listed in Table 2-7. In this
experiment, the drug content in each unit dose was identical for all tested formulations
(ODF and ODT). The results indicated that microparticles in either ODT or ODF
successfully alleviated drug bitterness down to an acceptable level (score≤1). ODT with
microparticles completely masked the bitterness of Chlorpheniramine Maleate(score=0);
in contrast, slight bitterness (score=1.1) was observed for ODT controls. In addition,
ODF with microparticle assuaged the intensity of bitterness remarkably from moderate
(score=2) to slight (score=1). We also noticed that ODT formulations had a better taste
than ODF Formulations. Perhaps this could be explained by two reasons: (1) the
excipient mannitol (filler) in ODT has a sweet taste, which could improve the taste of
ODT; (2) ODF sticks easily on the tongue where released drug molecules and taste buds
are in contact. This is contrary to ODT since microparticles are swallowed directly after
disintegration. Therefore, we deduce that taste masking is associated with not only drug
dissolution, but with other parameters such as the type of the solid dosage form and the
selection of excipients.
2.4.

Discussion

It is well known that classical solid oral dosage forms such as tablets or capsules
are not appropriate for pediatric patients. Thus, alternative formulations are needed to
enhance patient’s compliance. Our intentions here were to enhance pediatric formulations
by designing taste masked microparticles of Chlorpheniramine Maleate using Eudragit®
EPO and incorporate these microparticles in pediatric friendly orally disintegrating film
and orally disintegrating tablet. Microparticles have been considered a feasible approach
for taste masking.5,6,39 Unfortunately, this approach has required complicated preparation
processes as compared to conventional methods for taste masking such as direct addition
of flavor/sweetener. Despite the complexity of forming microparticles, microparticles
have several advantages over flavor/sweetener additions particularly when the
conventional methods are sometimes not effective. This is true when the bitterness
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Table 2-7.

Taste masking evaluation.
Score
(Bitterness)
0 (None)
1 (Slight)
2 (Moderate)
3 (Strong)
Score Average

Observation of Individual Numbers (Total Number=10)
Film
Film
ODT
ODT
(Control)
(Microparticle)
(Control)
(Microparticle)
1
10
2
8
9
6
1
1
2
2
1
1.1
0
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sensation overpowers the sweetness effect.24 Alternatively, microparticles provide
practical solution because it inhibits the release of drug on the taste buds. In addition, it
decreases the amount of excipients needed to mask the taste the bitterness and provide
more convenient options for formulation scientists.
In this study, we approached the taste-masking project through optimizing
experimental variables with the aid of Design of Experiments (DoE). DoE has been
utilized widely as an organized approach to demonstrate the correlations between
experimental variables and responses.40 During formulation developments, experimental
variables can be either material variables (i.e. weight, volume, etc) or process variables
(i.e. rate, force, etc), while experimental responses can be product quantitative attributes.
DoE is highly utilized for small-batch formulation development and for scaling-up to
large-batch processes.40 Since it is quite unreasonable to study all parameters (inputs) and
all responses (outputs) simultaneously, DoE is generally utilized to optimize key inputs
and identify key critical outputs. In this study, an orthogonal experimental design L9 (33)
was introduced to investigate three important variables (the weight ratio of Eudragit®
EPO to drug, the volume ratio of dichloromethane to water, and Q-flow). Orthogonal
design, unlike empirical optimization methods, can emphasize the basic and eliminate the
need for a large number of undesirable experiments.41 As part of the design, we
correlated key variables and responses using polynomial regression mathematical
analysis which has been verified as an effective tool to develop formulations.33,42,43,44 The
results we obtained indicated that polynomial regression can precisely identify the
relationships between variables and responses and sequentially predict the performance
of formulations made by same variables at other levels (see Equation 2-7 and Table 2-2).
This model enabled us to select microparticles from Formulation 7 for further exploration
due to relatively high drug encapsulation efficiency (around 84%) and slow drug release
rate (only around 40% released within 24 hour). It is noticeable that the models we
developed in this study could only be applied for experimental variables under a finite
range (X1 from 5 to 10, X2 from 3 to 7, X3 from 30 to 45). In addition, the surface
response analysis cannot satisfy all formulation development requirements (e.g. a large
number of variables included in formulation process) since polynomial regression might
not be practical for variables with a high-order dimensionality.45 Thus, in these cases
artificial neural networks (ANN) is considered as an alternative.45,46 We explored two
oral dosage forms (ODF and ODT) which are suitable for pediatric patients. Since
unpleasant taste of the drug has already been attenuated by the formation of
microparticles, swallowing appropriateness is the other main concern for formulation
selection. Unfortunately, pediatric patients have difficulty to swallowing regular solid
dosage forms. And although liquid formulations are acceptable for children; its low
portability and drug stability may become an issue. On the premise of easy administration
and swallowing, ODF and ODT are concerned by pharmaceutical scientists.7
In this study, microparticles were successfully incorporated into both dosage
forms and the release profile of microparticles did not change significantly as dosage
forms (ODF or ODT) changed. In terms of acceptable taste-masking efficiency, these two
dosage forms with microparticle loading could serve as the first front for the oral delivery
of other bitter drugs for pediatric population. However, although these two dosage forms
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could both be successfully produced in small batches, there might be challenges for
future scaling-up and large-batch production. Formulation scientists and process
engineers might utilize Design of Experiment (DoE) as the key to overcome these
challenges.
2.5.

Conclusion

In this study, spray drying method is an appropriate method to produce
microparticles with expected drug encapsulation efficiency and drug release profile. Drug
encapsulation efficiency and release profile of microparticles made from various variable
levels could be predicted accurately and the optimized microparticles were obtained with
the aid of polynomial equations and response surface plots. The selected microparticles
were formulated into ODF and ODT with reliable and reproducible preparation processes
(small variations in weight as well as drug content, acceptable strength). The ODF and
ODT disintegrated in short period of time, which are qualified for orally disintegrating
dosage forms. Drug bitterness intensity was alleviated significantly in oral cavity, but
Eudragit® EPO did not slow drug release in stomach. In conclusion, both ODF and ODT
containing microparticles are potentially appropriate for pediatric uses.
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CHAPTER 3.

INFLUENCE OF SELECTED ANIONS ON MILLING OF
SULFAMERAZINE NANOCRYSTAL﹡
3.1.

Introduction

Solid oral dosage forms are user-friendly and therefore preferred over many other
dosage forms for systemic drug delivery. Typically, a satisfactory oral dosage form
requires acceptable bioavailability which is related to drug solubility, dissolution,
permeability and absorption. Unfortunately, many new drug molecules are hydrophobic
and have low oral bioavailability.47 To overcome this challenge, formulators have made
significant effort to enhance dissolution rate and solubility of drug molecules, particularly
those classified in the biopharmaceutics classification system (BCS) as Class II (high
permeability and low solubility) and Class IV (low permeability and low solubility). By
far, several approaches to enhance dissolution rate and solubility have been developed.
These include surfactants,48 amorphilization,49 polymorph transformations,50
complexation,51 salt formation,52 and self-emulsification drug delivery system
(SEDDS).53 Considering the current progress of formulation design concept from microsize level to nano-size level, nanocrystal technology has been matured and became an
effective methodology for solubility and dissolution rate improvements.54,55,56,57,58,59,60 In
contrast to other dissolution rate improvement techniques, nanocrystallization has many
benefits including no organic solvents involvement, high drug loading efficiency, and
good reproducibility.54 Improvement of drug dissolution by nanocrystallization relies
primarily on enlarging particles surface area and enhancing solubility of nanoparticles
(Noyes-Whitney equation). Currently, there are several techniques for forming
nanocrystals. In general, these methods can be divided into two main categories:
“bottom-up” technology and “top-down” technology. The “bottom-up” technology
includes recrystallizing nanocrystals from super-saturated solutions. Due to inherited
limitations of “bottom-up” technology such as wide variation in particle size distribution,
solid state transformation (physical instability), and scale-up difficulty, this technology is
not widely applied.54 On the other hand, the “top-down” technology which involves
methods for reducing particle size from micron range is more popular. One of the most
important “top-down” methods is wet bead milling which is chosen for making
nanocrystals quite frequently.61
In wet bead milling, drug particles and beads/pearls are milled in an aqueous
medium and particle size is reduced by intensive collision. Due to higher surface energy,
nanosuspensions have several folds of magnitude of internal energy as compared to that
of conventional suspensions. For this reason, a large quantity of stabilizers is required to
stabilize nanoparticles and either polymers or surfactants are used as stabilizers. During
the last decade, extensive and significant research has been carried out to evaluate the
﹡: Adapted with permission. Lou H, Liu M, Qu W, Johnson J, Brunson E, Almoazen H.
The influence of sodium salts (iodide, chloride and sulfate) on the formation efficiency of
sulfamerazine nanocrystals. Pharm Dev Tech. In Press.
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influence of stabilizers on wet milling. It is recognized that this influence may be caused
by the amount of stabilizer,62 its molecular weight,63 hydrophobicity/hydrophilicity,62 and
functional groups.64 Moreover, other milling parameters such as type of drug,62,65 milling
bead,65,66 milling frequency,67 and milling time67 were investigated.
As far as we know, wet milling has been explored in depth, but certain
information on few aspects were not explored and are worthy of further investigation. For
example, different salts (ions) could be dissolved in milling medium and their effects on
milling efficiency is worth to be explored. The key question is: whether the addition of
salts would positively or negatively affect milling? It must be noted that the influence of
several anions on hydrocarbons’ solubility (salting-in and salting-out effects) have been
studied.68 According to Hofmeister ion series, the ranking of anions were based on the
ability to increase surface tension of water and decrease the solubility of hydrocarbons in
water. These anions were ranked as follows: SO42->HPO42->OH->F->Cl->Br->NO3->I>SCN-. The anion to the left has the highest salting-out capability (increase surface
tension and decrease hydrocarbon solubility in water) while anions to the right have the
highest salting-in capabilities (decrease surface tension and increase hydrocarbon
solubility in water). Although this phenomenon has been studied and documented, its
implication on nanosuspension milling has not been studied yet. Briefly, the influence of
salts is believed to “make” or “break” water structure. However, new theories derived
from thermodynamic studies stated that the bulk water structure may not be enough
linked to the effect of Hofmeister ions ranking. Interestingly, few scientists illustrated
that ions, particularly anions, act directly on the first hydration shell of hydrocarbons and
the hydrocarbon’s surface tension as well as the ion binding capability.68 The influence of
anions in the Hofmeister series on hydrocarbon-water system has been applied in
pharmaceutical development. For example, various salts were selected and utilized to
prevent particle agglomeration during the coating process69 and to control the drug
release pattern.70
The effect of salts as described above led us to hypothesize that wet bead milling
might be influenced by the addition of salts since polymeric stabilizers play a critical role
in maintaining drug nanoparticles physical stability. The objective in this study was to
evaluate the influence of anions (sodium as cation) on nanocrystal formation by wet bead
milling. Sulfamerazine was chosen as the model drug. Sulfamerazine belongs to the
family of sulfonamide drugs, which are commonly used as antibacterial agents.
Sulfamerazine has very limited solubility in water.
3.2.

Experimental Procedures

3.2.1. Materials
Sulfamerazine were purchased from Sigma Aldrich (MO, USA). Zirconium oxide
beads (0.5 mm diameter) were purchased from NextAdvance (NY, USA). Trifluoroacetic

29

acid was purchased from Fisher Scientific (PA, USA). Polyvinylpyrrolidone (PVP) K30
was kindly donated by BASF (NJ, USA). De-ionized water was used in this study.
3.2.2. Wet-bead milling
Wet-bead milling was carried out using a Retsch Ball mill (Model MM200, PA,
USA). The frequency of vibration was kept constant at 30 Hz and the milling time was
maintained for 6 hours. One gram of Sulfamerazine, four grams of zirconium oxide beads,
and five milliliters of milling medium were loaded into a 10 mL stainless steel jar.
Milling mediums were PVP solutions (1% w/v) with and without salts. Three types of
salts were studied (sodium iodide, sodium chloride, and sodium sulfate) at three
concentrations of 0.1 M, 0.5 M, and 1 M.
3.2.3. Particle size measurement
Laser diffractometry (Micromeritics, GA, USA) with DigiSizer5200 software was
employed to analyze particle size distribution. Sulfamerazine saturated solution was
chosen as the background solution and powders were dispersed in this solution. Particle
size was expressed as volume distribution according to the Mie theory. Relative
refractive index of water (1.33) was included in the calculations used in this experiment.
3.2.4. Determination of PVP adsorption on particle surface
The amount of PVP adsorbed on particle surface was determined by subtracting
the PVP amount left in the solution after milling from total PVP amount in the initial
solution (initial solution is 1% PVP solution: 50 mg PVP in 5 mL milling medium
(theoretical); 49.6 mg PVP in 5 mL milling medium (actual)). All samples were first
filtered through a 0.22 µm membrane filter. A HPLC system (Shimadzu, Japan) which
included a solvent delivery module, a vacuum degasser, a column oven, and a diode array
detector was utilized to determine the amount of PVP in solutions. Aliquots of 10µL of
filtered samples were injected into a reversed phase C18 column (4 µm, 4.6×150 mm,
Waters, Ireland). The column temperature was maintained at 35 °C. The mobile phase
consisted of 0.01% (v/v) trifluoroacetic acid in water was supplied at a flow rate of 0.6
mL/min. The wavelength for PVP quantification was set at 200 nm.
3.2.5. Lyophilization
After 6-hours of ball milling, 5 mL of suspension was withdrawn from the jar and
lyophilized at -80 °C and 0.01 mbar for 60 hours (Labconco, KS, USA). Nano-micro
suspensions milled in medium without salt (Formulation 1) and in medium with 1 M
sodium sulfate (Formulation 2) were selected for lyophilization and further evaluation.
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3.2.6. Determination of drug content in lyophilized powder blends
To evaluate drug content in lyophilized powder blends, Sulfamerazine amounts
were quantified at 263 nm using a UV spectrometer (PerkinElmer, MA, USA) with
proper dilution. Briefly, 10 mg of powder blends were dissolved in 100 mL of de-ionized
water, followed by mechanical shaking overnight. Drug loading was characterized as the
percentage of drug amount in the powder blend.
3.2.7. Powder dissolution tests
In-vitro powder dissolution tests were performed using a USP paddle apparatus
(Hanson Research, CA, USA). Briefly, 25 mg of Sulfamerazine powder or powder blend
equivalents to drug content (lyophilized) were first dispersed in 2 mL of de-ionized water
with manual shaking. This suspension was prepared in order to break any loose
agglomerates.
Afterwards, the suspension was loaded to 500 mL of de-ionized water. The
temperature was maintained at 37 °C. Paddle rotation speed was kept constant at 25 rpm.
Powders of lyophilized Formulation 1 and Formulation 2 were evaluated for dissolution
test and conventional Sulfamerazine was utilized as the control. The concentration of
Sulfamerazine was monitored at 263 nm using a UV spectrophotometer. Three replicates
were carried out for each sample.
3.2.8. Differential scanning calorimetry
DSC Q2000 (TA Instruments, New Castle, DE, USA) equipped with a nitrogen
cooler that purge nitrogen gas at 50 mL/min was utilized to explore the thermal behavior
of the samples. The instrument was calibrated using Indium standard. Four samples
(approximately 5 mg each) were tested. These included sodium sulfate, conventional
Sulfamerazine (crystalline), lyophilized powder of Formulation 1, and lyophilized
powder of Formulation 2. Samples were first sealed in an Aluminum pan. Thereafter,
samples were heated at 10 °C/min from 25 to 250 °C.
3.2.9. Stability tests
Lyophilized powders from suspensions were stored at 25 °C/65% RH. Particle
size distribution was analyzed again after one month according to parameters in Section
3.2.3.
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3.3.

Results

3.3.1. Particle size measurement
It has been reported that wet bead milling is an effective method to reduce particle
size to the nanometer size.57,58,59,60,61,62,63 In this study, the effect of the anions of various
sodium salts in the suspension medium on wet milling efficiency was investigated; other
important parameters such as milling frequency, milling time, amount of drug, amount of
stabilizer PVP (K30), beads, and medium volume were kept constant. The average
diameters (d (v, 0.1), d (v, 0.5), and d (v, 0.9)) for 10%, 50%, and 90% of all measured particles
after milling were plotted in Figure 3-1. Figure 3-1 shows particle diameters for milled
suspensions without salts, and with 0.1 M, 0.5 M and 1 M of NaI, NaCl and NaSO4
respectively. Before milling, the particle size distribution of Sulfamerazine powders was
in the micron range and hardly any particles were in nanometer range since d (v, 0.1) was
10.1±2.9 µm, d (v, 0.5) was 31.1±0.5 µm, and d (v, 0.9) was 84.1±2.4 µm. After milling,
Sulfamerazine particle size was reduced significantly and the majority of particles d (v, 0.9)
was in the lower micron range. Since all the mediums used for milling contained 1% (w/v)
of PVP, the one which had no salt used as a control. After milling, the d (v, 0.5) was
1.665±0.101 µm for this control and approximately 20.9% of total volume of powders
were below 1µm (see first bar in Figure 3-1). The volume percentiles of particles with a
diameter less than 1 µm were plotted in Figure 3-1b. As can be seen in Figure 3-1b, the
volume percentile for the majority of particle size distributions for the milled suspensions
which contained sodium iodide and sodium chloride were below 30% including the
0.1 M of sodium sulfate suspension. The student t test was utilized to analyze statistical
significance, the 1 M sodium iodide was not statistically significant as compared to
control. The 1 M sodium chloride was statistically significant as compared to control
(p<0.05) and the 1 M sodium sulfate was more statistically significant (p<0.01).
Although this effect was not very obvious at sodium sulfate concentration of
0.1 M which showed a d (v, 0.5) value of 1.653±0.024 μm and a volume percentile of 21.2%
for particles diameters below 1µm, interestingly, the particle reduction became
significant as sodium sulfate concentrations increased to 0.5 M where (d (v, 0.5) was
1.285±0.023 μm and the volume percentiles of particles with a diameter below 1µm was
32.4%. As the sulfate concentration increased to 1 M, the d (v, 0.5) became
0.934±0.015 μm and the volume percentiles of particles with diameters below 1µm were
55.3%. According to the classification of Van Eerdenbrugh and coworkers, the milled
suspension with sodium sulfate (1 M) is Nanosuspension since more than 50% of the
volume of particles was below 1 µm and d (v, 0.9) was below 2.5 µm.62
A possible explanation for the effect of salts on particle size is related to the tested
anion which can decrease the stabilizer’s (PVP) solubility in water and consequently
enhance the adsorption of the stabilizer onto the Sulfamerazine particle surface.
Nanoparticles typically have higher surface energy as compared to the micron range
particles and are not thermodynamically stable due to particle aggregation and/or crystal
growth. To stabilize a nanosuspension, polymeric stabilizers are introduced to stabilize
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Figure 3-1.
1 µm.
**:

Particle size and volume percentiles of particles in suspensions below

p<0.01; *: p<0.05; o: no significant difference.

33

the nanoparticles and one of the critical requirements for selection of a stabilizer is its
ability to adsorb onto drug particle surface.71 Thus, we hypothesize that sulfate ions at
relatively high concentrations increases the total amount of PVP adsorbed onto particle
surface, thereby causing more stabilizing influence on nanoparticles stability and
enhancing the milling efficiency. This effect can be rationalize according to Hofmeister
ion series where the sulfate ion tends to break the water structure and influence the
hydration on the Sulfamerazine particle consequently increasing the adsorption of PVP
onto the particle surface. We have not considered conducting solubility of PVP in salt
solutions because PVP is freely soluble in water and viscosity becomes a limitation at
high concentrations.
3.3.2. Determination of PVP adsorption on particle surface
Several scientists illustrated that the adsorption of polymers onto solid surface is
critical for nanoparticle stabilization by weak interactions such as steric forces.72 Ploehn
and Russel referred to the adsorption of polymer as a compensation of free energy
reduction over entropy loss.73 It has also been reported that anions in the Hofmeister
series have important effect on polymers’ solubility and adsorption onto solid
surfaces.68,74 Therefore, the quantitative determination of polymer adsorption on particle
surfaces is an important and efficient approach to validate this assumption. As we
mentioned, the function of (PVP) during milling is the adsorption onto the surface of the
drug particle (described in Section 3.3.1). The amounts of PVP adsorbed onto drug
particle surface were calculated by measuring the depletion of PVP from the medium.
Adsorption data are listed in Table 3-1. As we observed, anions (sulfate, chloride,
and iodide) have different influences on PVP adsorption. The total amount of adsorbed
PVP for control (no salt) was 4.9±2.0 mg/g and 4.8±1.9 mg/m2. It was shown that as
iodide salt was applied regardless of different concentrations, the total amount of
adsorbed PVP was negligibly different to that without salt (control). On the other hand,
chloride and sulfate salts increased PVP adsorption considerably, especially at higher
concentrations; it was indicated that 12.5±2.5 mg/g PVP was adsorbed with sodium
chloride (1 M) and 20.2±0.8 mg/g PVP was adsorbed with sodium sulfate (1 M)
respectively. In view of this, we could lead to a conclusion about the rank of capability of
anions’ influence on PVP dehydration which is sulfate>chloride>iodide. Moreover, by
tying these values to particle size values, it is worth suggesting that the stabilization of
particle size in nanometer level might be partly due to more PVP which covers larger
surface area of nanometers. Additionally, it is logically hypothesized that more PVP
molecules consequently have higher steric interaction to stabilize the nanosuspension.
3.3.3. Lyophilization
Spray drying and lyophilization are currently the two most typical methods for
drying suspensions.74 In this study, we anticipated the circulation of spray dryer would
easily be clogged by viscous milled suspensions and therefore we decided not to use the
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Table 3-1.
The amounts of PVP adsorbed onto Sulfamerazine particles after
milling at concentrations.
Milling Medium
PVP Solution 1%
(with or without Salt)
No salt
Sodium Iodide 0.1 M
Sodium Iodide 0.5 M
Sodium Iodide 1 M
Sodium Chloride 0.1 M
Sodium Chloride 0.5 M
Sodium Chloride 1 M
Sodium Sulfate 0.1 M
Sodium Sulfate 0.5 M
Sodium Sulfate 1 M

PVP in
Solution after
Milling
(mg)
44.7±2.0
45.2±1.3
45.3±1.6
44.2±0.7
44.0±2.3
39.3±2.8
37.1±2.5
42.0±2.1
37.3±0.9
29.4±0.8
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PVP Adsorbed onto
Sulfamerazine
Particle Surface
(mg/g)
4.9±2.0
4.4±1.3
4.3±1.6
5.4±0.7
5.6±2.3
10.3±2.8
12.5±2.5
7.6±2.1
12.3±0.9
20.2±0.8

spray dryer; instead, we removed water by lyophilization. We lyophilized two
suspensions, the first suspension was milled in medium containing no salt
(Formulation 1); and the second suspensions was milled in medium containing 1 M
sodium sulfate (Formulation 2) which exhibited the highest percentage of particles in
nanometer size. After drying, loose agglomerates were observed in both powder blends.
One explanation for this phenomenon is the existence of capillary forces during drying
and which could be the factor of nanoparticle agglomeration.75 Moreover, particle size
measurements indicated that these agglomerates were too loose and broke easily upon redispersion. As shown in Figure 3-2, there were no particle size changes for Formulation
1: d (v, 0.5)=1.615±0.026 µm and the volume percentiles of particles with a diameter below
1 µm was 20.8% (after lyophilization); d (v, 0.5): 1.665±0.101 µm; the volume percentiles
of particles with a diameter below 1 µm: 20.9% (before lyophilization). On the other
hand, for Formulation 2, after lyophilization, particle size (d (v, 0.5): 1.085±0.127 µm; the
volume percentiles of particles with a diameter below 1 µm: 45.5%) increased slightly as
compared to that before lyophilization. Despite a slight increase of particle size during
drying, particle size of dried powders from suspension Formulation 2 was significantly
smaller than that of dried powders from suspension Formulation 1.In addition, percentage
of drug content in lyophilized powder blends was determined. Values are summarized as
follows: 95.6±4.4% for the sample obtained from the suspension Formulation 1 and
59.4±3.7% for the sample obtained from the suspension Formulation 2. Student t test
shows no significant difference of particle percentile below 1 µm for lyophilized
Formulations 1 and 2 and lyophilized Formulations 1 and 2 after 1 month (p>0.05).
3.3.4. Powder dissolution tests
Van Eerdenbrugh and co-workers indicated that nanoparticle agglomeration
occurs almost inevitably during drying with no addition of matrix former.74 Therefore, we
strive to preserve the nanoparticles in loose agglomerates that can break up easily. The
lyophilized powders of suspension Formulation 1 and suspension Formulation 2
deaggromerated in water via manual shaking, therefore, all powders were first
re-dispersed to form suspensions and then dissolution evaluation was performed for
powders in the suspended state. Moreover, the re-dispersed nanosuspension may be the
ideal formulation for dosing patients for two reasons: (1) nanoparticle advantages can be
retained; (2) this formulation can be prepared easily by patients at home on their own.
The dissolution profiles of conventional crystalline Sulfamerazine powder, the
lyophilized suspension Formulation 1 (control), and the lyophilized suspension
Formulation 2 (1 M sodium sulfate) are plotted in Figure 3-3. Typically, particles in
suspensions dissolve faster than dry powders, especially for hydrophobic materials, since
wetting process takes time. As expected, the lyophilized Formulation 1 released 86% of
Sulfamerazine within 5 minutes while the lyophilized Formulation 2 released 95% of
Sulfamerazine within 5 minutes. Both profiles were significantly faster as compared to
conventional crystalline Sulfamerazine powder which 67% had released within 5 minutes.
This indicates that wet bead milling is an effective method for dissolution rate
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Figure 3-2. Particle size and volume percentiles of particles below 1 µm of
lyophilized formulations.
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Figure 3-3.

Dissolution profiles of Sufamerazine.
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enhancement of Sulfamerazine. In addition, the difference of dissolution rate between
powder of lyophilized Formulation 2 and powder of lyophilized Formulation 1 is
relatively small but still distinguishable. This difference partially attributed to the fact
that powders of lyophilized Formulation 2 had smaller particle size. Although this
dissolution tests provided a sound validation to the assumption that nanocrystals leaded to
higher dissolution rate, the correlation between dissolution and particle size could not be
established here.
3.3.5. Differential scanning calorimetry
DSC is utilized to characterize crystalline states and phase transitions of solids. It
has been reported that Sulfamerazine has two polymorphs (I and II) and these two
polymorphs are enantiotropic polymorphs.76 Zhang et al also revealed that polymorph II
transforms into polymorph I at 173-175 °C with an endothermic peak, and then
polymorph I shows a significant endothermic peak and melts at around 240 °C.76 In this
experiment, to confirm whether there is a phase transformation of Sulfamerazine during
milling and lyophilization, lyophilized samples were evaluated by DSC. All DSC
thermograms are shown in Figure 3-4. There was no phase change identified for sodium
sulfate in the studied range. Clearly, the DSC thermograms indicate that the conventional
Sulfamerazine exists as polymorph I since it indicates only an endothermic pick at around
238 °C.76 In addition, both powders of lyophilized Formulation 1 and powders of
lyophilized Formulation 2 have very similar thermal behavior as conventional
Sulfamerazine since all samples melted at 235 to 238 °C. Therefore, both powders of
lyophilized Formulation 1 and lyophilized Formulation 2 exist as polymorph I. We can
conclude that no polymorphic phase transformations were observed during milling and
lyophilization processes.
3.3.6. Stability
Agglomerates could be observed in powder blends before and after stability tests.
These agglomerates could be removed via dispersing in a solution with shaking. Particle
size analysis revealed that there was no considerable change in particle size distribution
before samples which underwent 1-month stability test and fresh samples, as shown in
Figure 3-2.
3.4.

Discussion

Polyvinylpyrrolidone (PVP), a commonly-used stabilizer, was chosen and kept
constant in this study. Our intention is to investigate the influence of various anions in
Hofmeister series on wet milling. Salts such as sodium sulfate played a significant role on
increasing nano-microcrystal milling efficiency and were kept in lyophilized powder
blend. Therefore, the percentage of excipient (excipient loading) in powder blend is
worth to be noted. In lyophilized Formulation 2 powder blend, percentage of sodium
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Figure 3-4.

DSC patterns of various powder samples.
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sulfate was around 39% (w/w) and PVP was less than 3% (w/w). In other words, while
167 mg of Sulfamerazine needs to be dosed followed by a prescription using this
formulation, approximately 110 mg of sodium sulfate in the blend was also dosed. It is
necessary to point out that, at this dose level of sulfate, no considerable adverse effects
were observed and reported in previous human and animal studies.77 Additionally, this
study is a representative example of expanding a new application of Hofmeister since
series salts. Sodium sulfate, in this study, had a “salting-out” effect, which lead to an
increase of milling efficiency (Formulation 2 with 1 M sodium sulfate, 55.5% of particles
less than 1 µm vs. Formulation 1 without salt, 20.9% of particles less than 1 µm).
Oppositely, sometimes “salting-in” effect is pursued and applied. For example, more
organic solvent can be miscible with aqueous phase with the aid of “salting-in” effect. In
this scenario, some anions ranking at the right side of Hofmeister series such as Iodide
may be considered. Since salts in Hofmeister series influence the alignment and quantity
of hydrocarbons including various amphiphiles at different interfaces (e.g. liquid/liquid,
liquid/solid, liquid/gas), the potential expansion of its pharmaceutical application is quite
promising and may encompass multiple fields including liquid formulation production
(e.g. emulsion, suspension, gel, cosolvent, micelle, protein/peptide formulations) and
solid dosage form development (e.g. coating, wet milling). This study also indicated that
nonocrystallization is an effective and stable method for dissolution rate enhancement of
poorly-water soluble drugs. Moreover, most excipients that enhance the production
efficiency of nanocrystals are cost-economical and therefore have the potential feasibility
for large-batch size utilization. Despite the fact that considerable percentage of excipients
in lyophilized powder blend, drug loading in this product is still generally higher than
another prevalent drug dissolution enhancement approach: amorphous solid dispersion, in
which large amounts of excipients are usually necessitated to stabilize drug in amorphous
state.78,79,80 In light of dissolution enhancement, a new concept which combines these two
techniques has been developed: amorphous drug nanoparticles. Amorphous drug
nanoparticles can be produced by some specific “bottom-up” methods, similar as
nanocrystal “bottom-up” methodology, and eventually dispersed in aqueous phase as an
amorphous nanosuspension. This novel nano-level formulation, may offer an even higher
saturated solubility and faster dissolution rate as compared to regular nanocrystals.81
Unfortunately, instability is a challenging obstacle for this technique’s maturation. As a
consequence, in amorphous nanosuspension system, it is very likely to form small
amounts of nucleus and/or crystalline particles, and then crystals keep growing as
amorphous nanoparticles dissolve simultaneously,81 which results in the lost of
solubility/dissolution advantage.
3.5.

Conclusion

In this study, it was shown that wet bead milling is a successful approach to
reduce particle size of Sulfamerazine. Sodium sulfate (1 M) in milling medium could
enhance milling efficiency of drug particles significantly and a higher percentage of
particles were in nanometer level but other salts had minimal effects compared to control.
Furthermore, powders after milling and lyophilization processes showed remarkable
dissolution rate improvement.
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CHAPTER 4. DEVELOPMENT OF A COATED MINI-TABLET OF COGRINDED PREDNISONE–NEUSILIN COMPLEX FOR PEDIATRIC USE﹡
4.1.

Introduction

Due to the lack of pediatric formulations, the regulatory agencies have initiated
continual emphasis on the necessity for developing novel pediatric formulations. In
response, pharmaceutical companies have developed various novel pediatric formulations
some of which have already been launched into the market.1
In general, oral delivery of pediatric drugs is preferred over other delivery routes
since it is convenient, economical, and user-friendly.1 In this study, we utilized
Prednisone as a model drug and provided formulation methods for developing an oral
solid dosage form that can be compatible with pediatric patients. Prednisone is a
glucocorticoid prodrug which converts to its active metabolite Prednisolone in the liver.82
For decades, this drug has been involved widely in pediatric therapies. At low doses,
Prednisone is involved in the treatment of emergency rescues such as acute asthma.83 At
relatively high doses, Prednisone is prescribed for the treatment of pediatric cancer.84
Although Prednisone has therapeutic uses for many pediatric diseases, there are several
challenges that should be addressed with the oral delivery of this drug. These challenges
include: (1) this drug is sparingly soluble in water and has low bioavailability; any liquid
formulation must include organic solvents; (2) this drug has low tolerance depending on
the dose strength and can cause fluctuation in overall absorption; (3) this drug should be
in a dosage form that could be swallowed readily; (4) this drug is extremely bitter which
requires better palatability through taste masking.
To improve the dissolution rate of poorly-soluble drugs, a number of approaches
have been reported including amorphilization,49 nanocrystal,55,85,86 complexation,51 salt
formation,52 and polymorph transformation.50 Although an amorphous form dissolves
faster than a crystalline form, amorphous solids retain higher free energy levels which
cause the solid to become unstable and inherit the tendency to convert to the crystalline
form. In order to stabilize amorphous molecules during the storage and dissolution
process, preparing solid dispersion is one approach and various polymers such as PVP,
PEG or cellulose derivatives have been widely used as dispersants.87,88 In contrast to
organic polymers, Neusilin can also function as a carrier to keep drug in amorphous
state.89,90 Neusilin® US2 is a porous granule of amorphous magnesium aluminosilicate
which retains a tremendous surface area (around 300 m2/g). The surface of Neusilin
contains a large amount of silanol functional groups which facilitate the formation of
hydrogen bonds.91,92,93 After cogrinding a drug with Neusilin® US2, an amorphous drugNeusilin complex is formed.89,90,94 One possible mechanism for the formation of
﹡: Adapted with permission. Lou H, Liu M, Wang L, Mishra SR, Qu W, Johnson J,
Brunson E, Almoazen H. Development of a mini-tablet of co-grinded prednisone-neusilin
complex for pediatric use. AAPS PharmSciTech. In Press.
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amorphous complex is linked to the crystalline structure disruption which is caused by
force of mechanical shearing during milling then followed by the adherence of
amorphous pieces into Nuesilin® US2 surfaces by hydrogen bonds or salt bridge
formation.91 It is well known that Neusilin® US2 is involved in solid dosage form not
only as an adsorbent but also as a low-toxicity excipient which can increase tablet
hardness.95
Swallowing ability is critical for pediatric formulations. Regular solid dosage
forms such as capsules or tablets are unfortunately not suitable for pediatric population
since essentially children less than 10-year-old are not able to grasp the skills of
swallowing regular size tablets or capsules. Although granules and powders are suitable
replacements for tablets or capsules, particle size must be characterized to prevent any
dose fluctuations. To achieve swallowing appropriateness and good unit dose strength,
mini-tablet is a suitable candidate. Mini-tablet is defined as a tablet with a diameter less
than 3 mm.13 A recent study conducted by Thomson et al. illustrated that out of 100
preschoolers, no one suffered the potential of choke caused by swallowing placebo minitablets and up to 86% of 5-year-old children swallowed mini-tablets successfully.14
Additionally, the manufacturing procedures of mini-tablets can be scaled-up since minitablets can be compressed by regular tablet press with reproducible sizes, weights, and
dose strengths.15
If a pharmaceutical compound or an excipient has poor pediatric compliance due
to unpleasant taste, film coating with a polymer is a realistic solution. For instance,
Eudragit® EPO is s a taste-masking and moisture protective material which has been
extensively applied in film coating.29 Since it is a pH-dependent copolymer, it is only
slightly swellable when the pH is higher than 5 and is completely soluble when the pH is
lower than 5. Therefore, Eudragit® EPO film coating can be used to achieve taste
masking in the oral cavity (pH=6.8) while keeping the immediate release characteristics
for the dosage form in stomach (pH=1.2).
The objective of this study was to develop a novel pediatric formulation for
Prednisone. In this study, dissolution rate of Prednisone was enhanced after cogrinding
Prednisone and Neusilin to form an amorphous complex. Moreover, this complex was
compressed with other excipients into 2 mm diameter mini-tablets. Lastly, Eudragit®
EPO multiple layers were coated on the mini-tablet for taste-masking purpose.
4.2.

Experimental Procedures

4.2.1. Materials
Prednisone was purchased from Sigma Aldrich (MO, USA). Neusilin® US2 was
kindly donated by Fuji Chemicals (NJ, USA). Eudragit® EPO is poly (butyl methacylateco-(2-dimethylaminoethyl) methacrylate-co-methyl methacrylate) and was kindly
donated by Evonik (NJ, USA). Croscarmellose sodium was kindly donated by FMC
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Biopolymer (PA, USA). Magnesium stearate was kindly donated by Mallinckrodt (MO,
USA). Silicified microcrystalline cellulose was kindly donated by JRS Pharma (NY,
USA).
4.2.2. Milling
A Retsch Ball mill (Model MM200, PA, USA), attached with a 25 mL stainless
steel jar and 5 mm diameter stainless steel ball, was used to grind Prednisone with and
without Neusilin® US2. The frequency of vibration was kept constant at 4 Hz and the
milling operation time was maintained for 90 minutes. A 1 gram of Prednisone with
variable amounts of Neusilin® US2 at various ratios (1:1, 1:3, 1:5, and 1:7) were
physically mixed and then milled at room temperature. After ball milling, samples were
transferred to a loosely capped glass vial, and stored in vacuum at room temperature.
4.2.3. Differential scanning calorimetry studies
The thermo behavior of samples were explored using a DSC Q2000 (TA
Instruments, New Castle, DE, USA) which is equipped with a nitrogen cooler at
50 mL/min nitrogen purge. The instrument was calibrated using Indium standard. Seven
samples (about 5 mg each) were tested including Prednisone, Neusilin® US2, 1:1
Prednisone/Neusilin® US2 physical mixture, and co-ground 1:1, 1:3, 1:5: and 1:7
Prednisone/Neusilin® US2 complex. Samples were first sealed in an Aluminum pan and
held at 40 °C for 2 minutes. Thereafter, samples underwent modulated heating rate at
5 °C/min associated with 0.5 °C modulation amplitude every 40 seconds. The overall
temperature scan ranged from 40 to 300 °C.
4.2.4. X-ray powder diffraction and percent crystallinity
The X-ray powder diffraction of Prednisone, Neusilin and co-ground
Prednisone/Neusilin complexes at different ratios were obtained using Bruker AXS D8
advance diffractometer (Bruker, Germany) which is equipped with a copper anode (target,
Cu Kα radiation; voltage, 40 kV; current, 30 mA; divergence slit, 3.722 mm; antiscatter
slit, 3.722 mm; detector slit, 5 mm; Goniometer radius, 300 mm) at ambient temperature.
A thin layer of powder sample was first laid on a sample holder and then measured at 2θ
in a continuous range from 3° to 40° with a step size 0.048. The percent crystallinity of
samples was determined using Eva Software (Bruker). A two phase model was employed
in the determination of the degree of crystallinity; that is the sample is composed of
crystals and amorphous and no regions of semi-crystalline organization. Thus, the
diffraction profile was divided in 2 parts: peaks related to diffraction of crystallites and
broad region related to the scattering from amorphous phase. The assumption is that the
areas are proportional to the scattering intensities of crystalline and amorphous phases.
The percent crystallinity was calculated from the integrated intensities of all crystalline
peaks and the amorphous region under the diffraction curve. Percent crystallinity of

44

sample is defined as Icrystalline/(Icrystalline+Iamorphous). The contribution to the intensity from
the amorphous region in the sample was identified by properly adjusting the curvature of
the background curve. The contribution to the intensity from the crystalline region was
obtained after subtracting the above background curve from the XRD pattern.
4.2.5. Solubility measurements
Excess amounts of Prednisone or co-ground Prednisone/Neusilin® US2 complex
(1:7) were dispersed into 30 mL of simulated gastric fluid. The suspensions were placed
in a mechanical shaker at a constant shaking rate of 50rpm and a constant temperature of
25 °C. Two milliliters of liquid were withdrawn at each selected time point, filtered
through a 0.22 µm membrane filter, and diluted to an appropriate ratio using simulated
gastric fluid. The concentration of Prednisone was determined at 242 nm using UV
spectrometer (PerkinElmer, MA, USA). Three replicates were carried out for each sample.
4.2.6. Particle size measurement
Laser diffractometry (Micromeritics, GA, USA) was employed to analyze particle
size distribution. Saturated solution of Prednisone was chosen as the background solution.
Particle size measurement of suspension containing excess powder blend was performed.
Three replicates were performed for each sample. Particle size was expressed as volume
distribution according to the Mie theory. Relative refractive index of water (1.33) was
inserted in this experiment.
4.2.7. Surface area measurement
The specific surface area of each sample was determined by the gas adsorption
method according to the BET theory using “Gemini” surface area analyzer
(Micromeritics, GA, USA). Nitrogen gas was adsorbed to powder surface, and the
amount adsorbed gas was converted into the surface area of powder. Analysis was
performed at five relative pressures ranging from 0.05 to 0.2.
4.2.8. Morphology
Morphologies of Prednisone, Neusilin, and co-ground 1:7 Prednisone/Neuislin,
were characterized using the Environmental Scanning Electron Microscope (Philips,
Netherland) equipped with a Peltier stage. Prior to microscope observation, all samples
underwent platinum sputter-coating in argon.
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4.2.9. Core mini-tablet preparation
Three core mini-tablet formulations were prepared. Formulation 1 was directly
compressed from a powder blend of (75.2%) co-ground 1:7 Prednisone/Neusilin complex
containing (9.4%) Prednisone, (18.8%) silicified microcrystalline cellulose, (5%)
croscarmellose sodium, and (1%) magnesium stearate. Formulations 2 and 3 were
prepared as control groups. In Formulation 2, drug and excipients were identical to
Formulation 1, except for the use of 1:7 Prednisone/Neusilin physical mixtures. In
Formulation 3, no Neusilin granules were added; thus (9.4%) Prednisone was blended
and compressed with (84.6%) silicified microcrystalline cellulose, (5%) croscarmellose
sodium, and (1%) magnesium stearate. All mini-tablets were compressed into a biconvex
tablet with a diameter of 2 mm using a Carver hydraulic press (Carver INC, IN,
USA).The compression force was kept constant at 125 lb.
4.2.10. Characterization of core mini-tablets
4.2.10.1.

Thickness, weight variation and unit dose strength

Thickness of ten core mini-tablets for each formulation (Formulation 1, 2 and 3)
was determined using a vernier capiler. Weight variation was evaluated by weighing
mini-tablets (n=10).
To evaluate unit dose strength, ten core mini-tablets of each formulation were also
utilized. Briefly, each mini-tablet was dissolved in 25 mL of solution containing water
(68.8%), tetrahydrofuran (25.0%), and methanol (6.2%), followed by mechanical shaking
overnight to dissolve all Prednisone. The suspension was then filtered through a 0.45 µm
filter membrane, and the concentration of Prednisone was determined at 242 nm using
UV spectrophotometer.
4.2.10.2.

Tensile strength and friability

Tensile strength and friability of mini-tablets (Formulation 1) were conducted.
Tensile strength was calculated using the following Equation 4-1:
2∗F

d
Tensile strength=π∗D∗H

(Eq. 4-1)

Where Fd is tablet hardness, D is tablet diameter, and H is tablet central cylinder thickness.
Tablet hardness was determined using a manual tablet testing instrument (Vortex sales
group, NC, USA).
Friability tests were conducted using a friabilator (Sotax, MA, USA). Twenty
mini-tablets were first de-dusted, weighed, and laid into the friabilator drum with around
6 gram of 3 mm glass beads. One hundred revolutions were set. Friability was calculated
according to the following Equation 4-2.
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Percent Friability=

initial weight −final weight
initial weight

×100%

(Eq. 4-2)

4.2.11. Core mini-tablet coating
Due to the small mini-tablet size, mini-tablets could not be coated by fluid bed or
pan coating. Alternatively, dip-coating process was utilized to coat mini-tablets. A
coating solution consisted of Eudragit® EPO dissolved in acetone (20%, w/w) was
utilized for coating. The mini-tablets (Formulation 1) were dipped in Eudragit® EPO
solution for approximately 40 seconds and then air dried. Thereafter, a 15-second dipcoating process followed by air-drying was repeated 8 times. This group of coated minitablets was defined as Formulation 4. All coated mini-tablets were dried and stored in a
vacuum oven at room temperature.
4.2.12. Physical stability tests
The purpose of this study is to examine the influence of moisture on the physical
stability of Prednisone in the amorphous state over 4 week period. In this experiment,
core mini-tablets (Formulation 1) and coated mini-tablets (Formulation 4) were stored in
isolated desiccators at 75% RH (supersaturated sodium chloride solution) in a 25 °C oven.
4.2.13. Powder and mini-tablet dissolution tests
In-vitro powder dissolution tests were performed using the USP paddle apparatus
(Distek INC, NJ, USA). Five hundred milliliters of simulated gastric fluid (sodium
chloride 2 g/L; pH adjusted to 1.2 with hydrochloric acid) was maintained at 37 °C.
Paddle rotation speed was kept constant at 50 rpm. Briefly, 10 mg of Prednisone powder
or drug content equivalent to Prednisone/Neusilin complex was uniformly sprinkled to
the surface of the dissolution medium. Co-ground Prednisone/Neusilin complexes at
different ratios were evaluated and conventional Prednisone was utilized as the control
group. The concentration of Prednisone was monitored at 242 nm using an in-line fiber
optic cable connected to ultraviolet detector (pION, MA, USA). Three replicates were
carried out for each formulation.
Dissolution test parameters of core mini-tablets were kept constant as previous
powder dissolutions. Eighteen mini-tablets (equivalent to 10 mg of Prednisone) were
directly dropped into the dissolution vessel. Three formulations (Formulations 1, 2, and 3)
were evaluated and three replicates were carried out for each formulation.
Dissolution behavior of coated mini-tablets (Formulation 4) was evaluated in
simulated gastric fluid (pH=1.2) as well as in simulated saliva (pH=6.8). In addition,
dissolution rates of mini-tablets (Formulation 1 and Formulation 4) after stability test
were evaluated in gastric fluid (pH=1.2). Dissolution parameters (temperature, paddle
rotation speed, medium volume, and number of tablets) were kept identical to those of
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core mini-tablets. Three replicates were carried out for each formulation.
The dissolution profile similarity factor (f2), as shown in the following
Equation 4-3, was utilized to compare the dissolution profiles of mini-tablets before
stability test in Section 4.2.12 and after stability test.
f2=50×log{[1+(1/n)∑𝑛𝑛𝑡𝑡=1(R t − Tt )2]-0.5×100}

(Eq. 4-3)

Where (n) is the number of time points (10 time points, over 60 minutes), Rt is the mean
percentage of drug released for 1st curve at tt time point, Tt is the mean percentage of drug
release for 2nd curve at tt time point. Two dissolution profiles are considered similar if
f2≥50.
4.3.

Results and Discussion

4.3.1. Differential scanning calorimetry studies
DSC is utilized to evaluate thermal behavior and phase transitions of solids. It
provides useful information about the solid state properties (crystalline or amorphous) of
solid materials. All DSC thermograms are shown in Figure 4-1. Conventional Prednisone
thermogram shows an endothermic sharp peak at 235 °C. This refers to Prednisone
melting point and also suggests that Prednisone is in crystalline state. On the other hand,
Neusilin has no melting peak which is indicative of its amorphous state. Previous reports
in the literature showed that mixing Neusilin with volatile crystalline organic compounds
may transform these compounds from crystalline state into amorphous state.96 However,
the 1:1 physical mixture of Prednisone and Neusilin did not show considerable phase
transformation. Actually, the 1:1 Prednisone/Neusilin physical mixture showed an
endothermic peak at around 225 °C which indicates that Prednisone maintained some
crystallinity. We also noticed a shift in melting peaks for 1:1 physical mixture and
co-ground. This melting point reduction is linked to the interaction between Prednisone
and Neusilin. In a physical mixture, the addition of Neusilin attracts Prednisone crystal
aggregates and slightly lowers the melting point of Prednisone. In a co-ground mixture,
Neusilin and Prednisone have closer interaction since some of the aggregates may have
smaller size due to grinding and therefore Prednisone melting peak shifts to a lower
melting point. Hence, the heat of melting of 1:1 physical mixture of Prednisone and
Neusilin was 31.13 J/g and decreased to 25.13 J/g for 1:1 co-ground mixture. This
suggests a small reduction in crystallinity. It is likely that only a certain amount of
Prednisone could exist in amorphous state at 1:1 ratio, and the rest exists as small crystals
after milling due to insufficient Neusilin adsorption surface. As the amount of Neusilin
increases, the DSC curves of 1:3, 1:5, and 1:7 complexes show a complete disappearance
of Prednisone endothermic peak. Thus, further addition of Neusilin caused major
reduction in drug crystallinity. It was observed that when the content of Neusilin became
three times in magnitude the drug content or even higher (co-ground 1:3
Prednisone/Neusilin complex), the majority of Prednisone stays in amorphous state.
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Figure 4-1.

DSC patterns of various powder samples.
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Therefore, we reach a conclusion that amorphization of Prednisone was related to
the amount of Neusilin. A possible explanation for this phenomenon suggests that as the
total surface area of Neusilin® US2 increases, disrupted Prednisone slices would adhere
and settle onto the surface of Neusilin® US2 granules, thus inhibiting the reversion back
to the ordered crystalline structure.91
4.3.2. X-ray powder diffraction
Solids in crystalline state have intensive constructive reflections; however, those
in amorphous state do not reflect X-ray beam since they do not have long-range
molecular arrangement. The X-ray powder diffraction of conventional Prednisone and
Prednisone/Neusilin complexes at different ratios are shown in Figure 4-2. The X-ray
diffraction of Neusilin shows the absence of any peaks which exhibits the amorphous
nature of Neusilin. Prednisone reveals multiple diffraction peaks including two
predominantly split peaks at 14° and one peak at 18° as well as other minor peaks
(percent crystallinity: 86.9). Both the 1:1 physical mixture and co-ground complexes
indicate similar diffraction characteristics similar to conventional Prednisone. Moreover,
and as expected, the intensity of X-ray diffraction of 1:1 co-ground complex was slightly
smaller than that of 1:1 physical mixture. As the amount of Neusilin increased, all
intensities of characteristic peaks decreased remarkably. When the ratio of Prednisone to
Neusilin increased to 1:7, the two predominant split peaks at 14° and the one at 18° were
extremely low in intensity and all other minor peaks completely disappeared (percent
crystallinity: 25.1). Therefore, the X-ray diffraction suggested that most Prednisone in coground 1:7 complex was in amorphous state. We are led to the conclusion that the
increase in the amount of Neusilin reduced the crystallinity of Prednisone which was
consistent with previous DSC results.
4.3.3. Solubility measurements
According to previous literature, the solubility and dissolution rate enhancement
of drug in amorphous state is caused by the formation of disordered structure of
molecules which has more free energy as compared to the molecules in ordered
crystalline structure.97 The solubility of conventional Prednisone and co-ground 1:7
Prednisone/Neusilin complex were evaluated as a function of time in Figure 4-3.
Prednisone exists in the crystalline state with highly hydrophobic properties. Figure 4-3
showed that crystalline Prednisone reached an equilibrium solubility of 0.117 mg/mL
within 3 hours then held a plateau for up to 72 hours. As for co-ground 1:7
Prednisone/Neusilin complex, Prednisone reached a maximal solubility at 0.28 mg/mL
within 10 hours then plateaued for 72 hours. It was obvious that Prednisone/Neusilin
complex displayed about two folds increase in solubility. Therefore, an amorphous
Prednisone in the presence of Neusllin, could form a saturated solution and maintain
solubility for at least 72 hours under this experimental condition. Additionally, solubility
reduction was not observed in this experiment, which indicated that Neusilin granule may
be an inhibitor for reducing the recrystallization of Prednisone in saturated solutions.
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Figure 4-2.
samples.

X-ray powder diffraction patterns of various Prednisone powder
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Figure 4-3.

Kinetic solubility of Prednisone powder samples.
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4.3.4. Surface area and particle size measurements
It has been reported that the silanol groups which are situated on the surface of
Neusilin granules act as potential hydrogen bond acceptors.91,92 Therefore, it is likely to
form hydrogen bonds between Prednisone and silanol groups. Based on this assumption,
amorphous Prednisone was expected to adsorb onto the surface of Neusilin® US2.
According to the literature, by combining the results of surface area and particle size
analysis, the modality of the drug as either adsorbed to Neusilin surface or kept free in
the crystal form in addition to the state of Neusilin granule could be evaluated.90 Results
of particle size and surface area measurements were listed in Table 4-1. The
manufacturer of Neusilin® US2 reported that the mean particle size ranged from 60 to
120 µm and the specific surface area of 300 m2/g. This was consistent with the
experimental values that we obtained milled Neusilin® US2 (mean particle size
88.62 µm; surface area 329.60 m2/g). Hence, Neusilin® US2 granule was intact without
fracture or breakage during the milling process under this shaking frequency. The high
surface area of Neusilin is related to its porous nature and the exposed surface.
Prednisone crystals had smaller mean particle size of 6.36 µm and surface area of
3.31 m2/g. To further clarify Prednisone adsorption to Neusilin, we need to pinpoint that
Prednisone crystals were disrupted during ball milling and slices of Prednisone in the
amorphous form were adsorbed to Neusilin. Thus, the particle size distribution of
co-ground Prednisone/Neusilin complex was expected to be similar to that of Neusilin
granule alone. On the other hand, the surface area of the complex was lower than that of
Neusilin granules because Prednisone slices covered and/or occupied the surfaces of
Neusilin. Mean particle size values of co-ground 1:7 Prednisone/Neusilin complex was
87.74 µm and total surface area was 271.79 m2/g. Therefore, this explains the particle
size distribution and the lower surface area of Prednisone as compared to those of
Neusilin. It was noted that as the content of Neusilin in the complex decreased, particle
size distribution D10, D50, D90, and Mv shifted to smaller values. This in part is due to the
existence of drug crystals in 1:1 complex (mean particle size: 66.67 µm) and 1:3 complex
(mean particle size: 75.95 µm). Moreover, the decrease of Neusilin content in the
complex resulted in a decrease in surface area; e.g. 1:1 complex (surface area:
157.15 m2/g); 1:3 complex (surface area: 229.04 m2/g). These surface area values could
be reasoned by (a) drug crystals that remained in the complex after co-grinding had
relatively smaller surface area; and (b) porous surface on the Neusilin were covered by
amorphous drug so that surface area was further decreased.
4.3.5. Morphology
The morphologies of Prednisone and Neusilin were directly visualized by
Scanning Electron Microscope (SEM). This experiment enabled us to observe the
adsorption of Prednisone to Neusilin surfaces. As seen in Figure 4-4, after cogrinding
(ball milling), Neusilin® US2 granules were kept intact. It could be seen that Neusilin
granules had a spherical shape and wide particle size distribution as was also verified by
particle size measurement using laser diffraction. In addition, the surfaces of granules
were not smooth, rather porous.
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Table 4-1.

Surface area and particle size analysis of various powder samples.

Sample
Prednisone
Co-grinded 1:1 D/N
Co-grinded 1:3 D/N
Co-grinded 1:5 D/N
Co-grinded 1:7 D/N
Milled Neusilin®

D10 (µm)
1.44
5.71
11.44
16.16
33.24
34.16

D50 (µm)
4.83
54.14
78.48
88.81
90.85
90.89

D90 (µm)
12.12
144.05
144.06
158.59
160.58
161.63

D/N: Drug/Neusilin Complex.

Figure 4-4.

SEM micrographs of Prednisone powder samples.

(a) Neusilin; (b) Prednisone; (c) Co-grinded 1:7 drug/Neusilin complex.
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Mv (µm)
6.36
66.67
75.95
83.29
87.74
88.62

Surface Area (m2/g)
3.31
157.15
229.04
252.07
271.79
329.60

It was noted the crystals had a smaller size as compared to Neusilin granules. The
particle size of Prednisone as obtained by SEM was less than 10 µm. This is consistent
with the previous particle size measurement. The morphology of co-ground 1:7 complex
is shown in Figure 4-4. We noticed that most Prednisone particles were adsorbed onto
the surface of Neusilin and only some particles were left free. This observation verified
our assumption that Neusilin functioned as an adsorbent that enabled the amorphization
of Prednisone. It was also observed that the porous surface of Neusilin was partially
covered by Prednisone particles which were responsible for surface area reduction of
Neusilin granule. Finally we need to mention that Neusilin maintained its original
spherical shape and size after grinding.
4.3.6. Characterization of core mini-tablets
The three mini-tablet formulations which were prepared are shown in Table 4-2.
The unit dose of Prednisone in each tablet was about 0.5 mg which was therapeutically
appropriate for pediatric indications. Tablet thickness, total weight, and drug content
were consistent among the three formulations which suggest that single compression
maintained constant mini-tablet characteristics during the compression process. In
addition, results of tensile strength (4.01±0.31 MPa) and friability tests (0.21%) indicated
that mini-tablets of Formulation 1 containing co-ground 1:7 Prednisone/Neusilin complex
had acceptable mechanical properties.
4.3.7. Powder and core mini-tablet dissolution profiles
Dissolution profiles of co-ground Prednisone/Neusilin complexes at different
ratios of 1:1, 1:3, 1:5, 1:7 and conventional (crystalline) Prednisone are shown in
Figure 4-5. The dissolution profile of crystalline Prednisone (control) indicated that up to
30% of the drug had dissolved within 20 minutes and around 70% dissolved within 90
minutes. It is worth mentioning from these results that the amounts dissolved were related
to the weight ratio of Prednisone to Neusilin.
The observed differences in dissolution rates were related to the co-existence of
amorphous and crystalline forms of Prednisone. At the low ratio of Prednisone in the
complexes (i.e. a ratio of 1:7), more amorphous form resulted in faster dissolution rate.
This was consistent with the observations of other researchers who investigated
dissolution rate enhancement caused by different ratios of drug to excipient.98,99 As the
Neusilin ratio decreased, more Prednisone is present in the crystalline state and less
amorphous form is adsorbed onto the surface of Neusilin granules which leads to slower
dissolution rate. Moreover, it is important to mention that incomplete release of
amorphous form may also be related to the formation of gel-like mass, which was
discussed by Law and co-workers.100 In order to prepare mini-tablets, and since powder
complex ratio at 1:7 exhibited the fastest dissolution profile as shown in Figure 4-5, a coground Prednisone to Neusilin complex at 1:7 was selected for mini-tablet (Formulation
1). In addition, physical mixture at the same ratio and crystalline Prednisone mini-tablets
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Table 4-2.

Characteristics of mini-tablets.
Formulation
1
2
3

Thickness
(mm)
1.93±0.03
1.92±0.01
1.84±0.01

Weight
(mg)
5.23±0.14
5.23±0.19
5.40±0.25

Unit Dose
Strength (mg)
0.55±0.01
0.54±0.01
0.56±0.01
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Tensile Strength
(MPa)
4.01±0.31
NA
NA

Friability
(%)
0.21
NA
NA

Figure 4-5.

Dissolution profiles of Prednisone powder samples.
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were also utilized as controls (Formulations 2 and 3).
The dissolution profiles of the three mini-tablets (Formulations 1, 2 and 3) which
were described are shown in Figure 4-6. The mini-tablets dissolution profiles in
Figure 4-6 show that 1:7 co-ground Prednisone/Neusilin tablets exhibited the fastest
dissolution profile (87% in 20 minutes) followed by 1:7 physical mixture (68% in 20
minutes) then the mini tablet with crystalline Prednisone (60% in 20 minutes). Previous
reports indicated that the disintegration time can positively influence the dissolution rate
of the drug from tablets.101 Therefore, mini-tablets are expected to disintegrate within a
short period of time in order to release Prednisone rapidly in gastric fluids. The presence
of Neusilin in the formulation improves the hardness and may cause a delay to the
disintegration process. In order to obtain a reasonable disintegration time, croscarmellose
sodium was added as a super-disintegrant. The dissolution profiles presented in
Figure 4-6 indicates that disintegration of mini-tablets was acceptable and did not inhibit
the dissolution rate of Prednisone. It is important to mention that crystalline form of
Prednisone in Formulations 2 and 3 dissolved much faster as compared to Prednisone
powders particularly during the initial stage. A possible explanation is linked to the
hydrophilic properties of the co-blended excipients which include silicified
microcrystalline cellulose and/or Neusilin. Both can enhance the wettability of
Prednisone powder. We can conclude from Figure 4-6 that Formulation 1 showed an
enhanced dissolution rate of Prednisone; therefore it is reasonable to say that Prednisone
remained in amorphous state during mini-tablet preparation and dissolution processes.
4.3.8. Coated mini-tablets dissolution profiles
Film coating of tablets is a widespread approach to inhibit contact between a drug
with unpleasant-taste and sensors of taste buds. It was reported that suppression of drug
release for only few minutes at the initial stage could reduce unpleasant sensations
associated with bitter taste of drugs.102 Eudragit® EPO, a pH-dependent copolymer, is
insoluble at pH above 5 but becomes soluble at pH below 5. Therefore, this polymer has
been selected as an appropriate material for taste masking purpose.29,103 Figure 4-7 shows
release behavior of Prednisone within coated mini-tablet in both simulated saliva solution
(pH=6.8) and in simulated gastric fluid solution (pH=1.2). It was observed that when
coated mini-tablets were placed in simulated saliva, the shape of the tablets was
unchanged for approximately 70 to 90 seconds then afterwards gel-like flocculants were
formed. Hypothetically, this may be due to the incomplete disintegration of coated minitablets after water penetration across Eudragit® EPO coating layer. The dissolution
profile of coated mini-tablet in simulated saliva confirmed the assumption that Eudragit®
EPO coating layer suppressed Prednisone release significantly (2% within 2.5 minutes).
However, in simulated gastric fluid, Eudragit® EPO dissolved rapidly and Prednisone
has dissolved with no barrier.
It is well known that exposure to moisture accelerates the re-crystallization
process of amorphous drugs and reduces the drug dissolution rate.104 Eudragit® EPO
coating has been noted to protect against moisture penetration.29 It is expected in this
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Figure 4-6.

Dissolution profiles of core mini-tablets.
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Figure 4-7.

Dissolution profiles of coated mini-tablets.
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study that it would decrease the moisture uptake of amorphous Prednisone, thereby
decreasing the re-crystallization process. Drug release behavior of Formulations 1 and 4
(after 1 month of physical stability evaluation) in simulated gastric fluid were plotted and
shown in Figure 4-8. The similarity factor value (f2) was calculated and a comparison
was made between the release profile of fresh coated mini-tablets (Formulation 4), and
coated mini-tablets (Formulation 4) after one month on physical stability (the f2 value
was 66.5). Also, a comparison was made between release profiles of fresh core minitablets (Formulation 1) and core mini-tablets (Formulation 1) after one month on physical
stability, (the f2 value was 46.6).In addition, a comparison was made between release
profiles of coated mini-tablets (Formulation 4) after one month on physical stability and
core mini-tablets (Formulation 1) after one month of physical stability (the f2 value was
70.7) respectively.
These values indicate that although there is no significant difference between drug
release profiles for coated and uncoated mini-tablets after 1-month of stability testing,
Eudragit® EPO coating had some influence on maintaining (moisture decreases
dissolution rate and therefore coating helps to maintain dissolution rate) drug dissolution
rate. A possible reason is that Eudragit® EPO coating somewhat decreased the exposure
of drug to moisture, which can minimize the drug re-crystallization; however, it was
concluded that re-crystallization of amorphous drug could not totally be inhibited by the
Eudragit® EPO coating during this limited time frame of 4 weeks. We like to show a
visual comparison in size between Formulations 1 and Formulation 4 (see Figure 4-9).
4.4.

Conclusion

This study demonstrated that co-ground Prednisone-Neusilin complex enhanced
drug dissolution rate due to a decrease in Prednisone crystallinity. Co-ground PrednisoneNeusilin (1:7) complex yielded reliable and reproducible preparation processes for minitablets. Eudragit® EPO coating (taste masking) suppressed the drug release from minitablets in simulated saliva (pH=6.8) while maintained immediate release properties in
simulated gastric media (pH=1.2). Thus, due to its small size, coated and uncoated minitablets of co-ground Prednisone-Neusilin can potentially be appropriate for pediatric use.
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Figure 4-8.

Dissolution profiles of mini-tablets after 1-month stability test.
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Figure 4-9.

Photos of Formulation 1 and Formulation 4.
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CHAPTER 5. DEVELOPMENT OF W/O MICROEMULSION FOR
TRANSDERMAL DELIVERY OF IODIDE IONS﹡
5.1.

Introduction

Iodide is vital for the biosynthesis of thyroid hormones triiodothyronine (T3) and
thyroxine (T4) in the thyroid gland. The deficiency of T3 and T4 leads to thyroid tissue
enlargement and other metabolic and physiological problems. It has been illustrated by
previous studies that iodide is massively accumulated in the thyroid gland regardless of
the dosing route.105,106 This accumulation is regulated by sodium-iodide symporter which
transports iodide from blood into thyroid epithelial cells.107,108 Typically, small amount of
iodide is used as a daily nutritional supplement to prevent iodine deficiency,109 whereas
much larger doses are used to avoid thyroid uptake of radioactive iodide following
nuclear fission accidents.110,111 Iodide is present in the typical diet, primarily through the
use of iodized table salt. Oral iodide can also be supplemented as potassium iodide
(available in both tablet and solution dosage forms) as well as with iodine strong solution
(Lugol’s solution). However, oral administration may not be ideal in certain populations
at greatest risk for iodine deficiency, such as infants or patients who suffered surgical
removal of GI tract. For this reason, transdermal drug delivery system may be an
appropriate alternative to oral delivery, particularly when oral absorption is compromised
in disease states characterized by malabsorption (e.g., short bowel syndrome). In contrast
to other drug delivery systems, transdermal administration offers advantages including
convenient, non-invasive, and continuous dosing and the avoidance of first-pass
metabolism.112
It is well understood that low molecular weight hydrophilic compounds including
ionized compounds can permeate through skin by appendage shunt pathways such as hair
follicles and sweat glands.113,114,115 However, the total amount of drug which can be
diffused via this route is limited because of its small surface area compared to the total
skin. In addition, it has been proposed that small ions can diffuse through lipid bilayer of
the stratum corneum by the “aqueous” or the “pore” pathway model.116,117,118 In this
model, pores are formed as a result of defects or imperfections in the interior structure of
lipid bilayer which leads ions to travel through more rigid tortuous routes.119,120
Depending on this model, ion diffusion through stratum corneum can be improved by
altering the porosity of lipid bilayer. Various types of penetration enhancers, such as
water, surfactants, fatty acids, and azones, can effectively influence the porosity of the
stratum corneum and further lower its resistance to chemicals.23 On the other hand, ion
penetration through the skin is also influenced by ion’s permeability. A recent report
demonstrated that anions have a faster diffusion rate than cations due to the presence of
negatively charged phospholipid groups in the stratum corneum.121 These findings
﹡: Adapted with permission. Lou H, Ni Q, Crill C, Helms R, Almoazen H. Development
of W/O microemulsion for transdermal delivery of iodide ions. AAPS PharmSciTech
2013;14:168-76.
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support our intent to deliver iodide ions through microemulsions. Microemulsion is a
multicomponent system composed of water, oil, surfactant, and cosurfactant.21 It has been
intensively utilized as a transdermal delivery system with several advantages including
low cost and simple preparation, long term product stability, and main ingredients acting
as solubilization and permeation enhancers.20,22,122 Microemulsion can potentially change
the internal structure of the lipid bilayer in the stratum corneum and enhance compound
penetration. Our aim is to develop an iodide transdermal delivery system which has
potential therapeutic uses when oral administration is not appropriate. In this study, a
W/O microemulsion system with potassium iodide (KI) was developed. Several
physicochemical characterizations were conducted to evaluate the system (e.g. pH,
droplet size, conductivity, viscosity, and stability). Franz diffusion cells were also utilized
to evaluate the penetration of the iodide ions through human skin.
5.2.

Experimental Procedures

5.2.1. Materials
Potassium iodide (KI), Span 20 and Pyrene were purchased from Sigma Aldrich
(St. Louis, MO, USA). Anhydrous ethanol was purchased from Fisher Scientific (Thermo
Fisher Scientific Inc, Pittsburgh, PA, USA). Capryol 90® was obtained from Gattefosse
(Lyon, France). De-ionized water was used in this study.
5.2.2. Construction of pseudo-ternary phase diagrams
Pseudo-ternary phase diagrams were constructed to evaluate the miscibility of the
basic components in the system at 25 oC. A series of different ratios (Km) of surfactant
(Span 20) to cosurfactant (ethanol) were prepared at 4:1, 1:1, 1:4, and 1:9, and then
followed by the addition of oil (Capryol 90®) at different weight ratios of oil to mixture
of surfactant and cosurfactant of 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 1:9
respectively. Water was titrated drop by drop to the three-component mixture (under
constant magnetic stirring) until a transition point where transformation from transparent
(optical monophase) to turbid (optical diphase) was reached. A boundary line connecting
all transition points was drawn, and the monophasic area AT beneath this boundary line
was calculated using Origin 8 software (OriginLab Corporation, Northhampton, MA),
which is shown in Figure 5-1. AT was used to evaluate water solubilization capacity into
the oil. The following solubilization capacities AT were calculated at different
surfactant:cosurfactant ratio Km (Km:4:1, AT:16.6, Km:1:1, AT:28.5, Km:1:4, AT:35.7,
Km:1:9, AT:37.4). The pseudo-ternary phase diagram at a constant surfactant/cosurfactant
ratio Km of 1:1 was chosen for further development because there is sufficient area in
pseudo-ternay phase diagram which could form micromeulsion at this ratio while
cosurfactant (ethanol) was kept relatively low in the formulation. A dilution line (L20)
was plotted linking 100% water to a mixture of oil and S/COS of 20% and 80% in
Figure 5-2.
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Figure 5-1. Pseudo-ternary phase diagrams of mixtures composed of oil (Capryol
90®), water, surfactant (Span 20), and cosurfactant (ethanol) at various S/COS
ratios (Km).
Shaded area represents the domain where the mixture system is monophasic.
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Figure 5-2.

Formulation selection from pseudo-ternary phase.

L20 is a dilution line which connects all formulations with a fixed ratio (20/80) of oil to
S/COS. Below the purple boundary line, the mixture exists as one phase, which is
represented by 1φ. Otherwise, the mixture is of multiple phases, which is represented by
M φ.

67

Data points on this line have a constant ratio of oil to S/COS of 1:4.123,124 The
intersection between the dilution and the boundary lines was recognized as the
formulation with maximum water solubilization capacity. Five selected formulations
(Table 5-1) with different water contents from L20 were further tested. Blank
formulations were first prepared by manually mixing Span 20, ethanol, Capryol 90®, and
water. Then formulations were incorporated with potassium iodide (KI) at a constant
concentration of 50 mg/mL by vortex mixing.
5.2.3. Droplet size measurements
The mean droplet size of selected formulations was determined by dynamic light
scattering using Zetasizer Nano ZS (Malvern Instruments Inc, Westborough, MA, USA).
Light was scattered at a fixed angle of 90°. Refractive index and viscosity values were
inputted into the program to determine the mean droplet size accurately. All
measurements were obtained at 25 oC. Triplicate measurements were taken.
5.2.4. pH measurements
The pH values of selected formulations were acquired using Orion 520A pH
meter (Thermo Fisher Scientific Inc, Pittsburgh, PA, USA). The pH probe was inserted
into 20 mL of liquids and values were recorded when the reading stabilized. All
measurements were done in triplicate.
5.2.5. Viscosity measurements
The kinematic viscosities of the selected formulations were determined using
Cannon-Fenske routine viscometer (Cannon Instrument Company, State College, PA,
USA) at ambient temperature. Kinematic viscosity was obtained by multiplying efflux
time of sample flowing through the capillary tube of the viscometer by the viscometer
constant. Thereafter, the dynamic viscosity was determined by multiplying the value of
kinematic viscosity by the sample density. All measurements were performed in triplicate.
5.2.6. Conductivity measurements
Conductivity measurements were performed using conductivity meter FE30/FG3
(Mettler-Toledo Inc, Columbus, OH, USA) at 25 °C. Conductivity diagram was obtained
through drop by drop water titration to the mixture of oil and surfactant/cosurfactant
(S/COS) at a constant ratio of 1:4 in a beaker. The conductivity sensor was soaked in the
liquid and the reading was recorded when the signal indicating the endpoint was achieved.
The conductivity of the five selected formulations after the incorporation of KI was
carried out using the same methodology. All measurements were carried out in triplicate.
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Table 5-1.

Formulation composition, pH and Z-average diameter at 25 °C.
Formulation

KI

pH

Z-average
Diameter (nm)

A

Water/Span20/Ethanol/
Capryol 90®
Composition (w/w %)
5/38/38/19

None

5.20±0.01

B
C
D
E
F

10/36/36/18
15/34/34/17
20/32/32/16
23/30.8/30.8/15.4
5/38/38/19

None
None
None
None
0.05 g/mL

5.13±0.01
5.00±0.01
4.94±0.01
4.82±0.01
5.68±0.00

G
H
I
J

10/36/36/18
15/34/34/17
20/32/32/16
23/30.8/30.8/15.4

0.05 g/mL
0.05 g/mL
0.05 g/mL
0.05 g/mL

5.60±0.01
5.40±0.01
5.38±0.01
5.32±0.01

Size under detection
limit
1.48±0.03
2.48±0.39
4.36±0.04
5.57±0.33
Size under detection
limit
1.07±0.06
2.19±0.15
2.88±0.21
4.51±0.15
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5.2.7. In vitro permeation studies
5.2.7.1.

Skin preparation

Human skin samples (chest and abdominal regions) were purchased from
National Disease Research Interchange (NDRI, Philadelphia, PA, USA). Subcutaneous
fatty tissues were removed from skin using a lancet after soaking the skin in a 60 °C
water bath for 1 minute.125 Thereafter, skin samples were washed with di-ionized water.
Prior to the actual permeation study, the fat free skin was stored refrigerated at 4 °C.
5.2.7.2.

In vitro diffusion experiments

To investigate KI formulation diffusion through the skin, Franz cells (PermeGear
Inc, Hellertown, PA, USA) were utilized. The receptor volume of each cell was 5 mL and
the diffusion area was 0.64 cm2. Prior to mounting the skin samples, each receptor was
filled with 5 mL di-ionized water. Successively the skin samples were clamped in
between the receptor (down) and donor (up) holding the stratum corneum side up. Prior
to the experiment, the jacketed receptor was kept for 1 hour at 37 oC using a water bath
with magnetic stirring. Afterwards, 1 mL of each selected formulation with 50 mg/mL KI
was loaded to the donor compartment and each donor cell was sealed with Parafilm® to
avoid the evaporation of formulation components. A KI solution (1 mL of 50 mg/mL
solution) was used as the control. Then, 250 µL of the aqueous liquid were withdrawn
from the sampling port of receptor and diluted with di-ionized water to 5 mL at different
time points (0 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h). Simultaneously, equal volume of diionized water was replaced into the liquid. The diluted samples were filtered through
0.45 µm Millex® filter (Millipore, Billerica, MA, USA) and analyzed using Orion iodide
selective electrode (Thermo Fisher Scientific Inc, Pittsburgh, PA, USA). Three replicates
were carried out for each selected formulation.
The concentration of iodide in the receptor at every time point was calculated
after incorporating the dilution factor. Then the cumulative amount of KI permeated
across the skin per unit area (mg/cm2) was obtained by using the following Equation 5-1.
−1
C n ×V 0 +∑ni=1
C i ×V i

Qn=

S

(Eq. 5-1)

Where Cn is the undiluted sample concentration (liquid concentration in the receptor) at
nth sampling time point, Ci is undiluted sample concentration (liquid concentration in the
receptor) at ith sampling time point, V0 is the receptor volume (5 mL), Vi is the sampling
volume (250 µL), and S is diffusion area (0.64 cm2). All Qn values at each time point
were plotted as a function of time. The steady state flux (Jss , mg/cm2 per hour) was
calculated for every formulation. Jss is the slope of linear portion of cumulative iodide
amounts.
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5.2.8. Accelerated microstructure stability testing
5.2.8.1.

Centrifugation

Selected formulations (2 mL) with and without KI were centrifuged at 13,000 rpm
(13,793 g) for 30 minutes using Eppendorf 5415C centrifuge.
5.2.8.2.

Thermal stability

Selected formulations (20 mL) were stored in sealed vials at a 40 oC stability
chamber for 4 weeks. Three replicates were carried out for each formulation.
5.2.8.3.

Chemical stability

Potassium iodide-starch test paper was utilized to test the existence of iodine.
Four standard iodine solutions (2.5E-2 mg/mL, 2.5E-1 mg/mL, 5E-1 mg/mL, 1 mg/mL)
were prepared by dissolving iodine in ethanol/water (50/50 w/w) solution. These
standards were utilized as indicators for any presence of iodine in microemulsion
formulations. Formulation J (23% water microemulsion with 50mg/mL KI) was selected
to observe the presence of iodine as a function of time (0 week, 2 weeks, and 4 weeks) at
ambient temperature. The test paper was dipped into the selected microemulsion for 30
seconds, followed by washing with a small volume of water to provide the aqueous
environment for the triiodide starch reaction.
5.3.

Results

5.3.1. Construction of pseudo-ternary phase diagrams
Non-ionic surfactants are utilized in topical formulations because they are less
irritating to skin and have less- tendency to cause allergic reactions.22 Moreover, it has
been reported that non-ionic surfactants with poly-ethoxylated groups and/or residues
may contain peroxides which accelerate the oxidation of iodide to iodine.126,127,128 For
this reason, Span 20 (HLB 8.6) was selected as the surfactant since it contains no
ethoxylated groups. In addition, Span 20 acts as a penetration enhancer which fluidizes
the intercellular lipid bilayer.129 However, the emulsification capacity of Span 20 is
limited since it has a relatively small polar group and a short nonpolar carbon chain. In
order to obtain a stable microemulsion system at relatively high water content, ethanol
was selected as a cosurfactant. Ethanol has been widely applied as a penetration
enhancer.23 Capryol 90® (HLB 6), a common penetration enhancer, was selected as the
oil phase.130,131 The formation of microemulsion is dependent on the assumption that
Capryol 90® interacts with the hydrophobic chain of Span 20 in the presence of ethanol
to lower the oil water interface. Pseudo-ternary phase diagrams were constructed to
evaluate the miscibility of the microemulsion components.132 Mixtures of Capryol 90®,
Span 20, ethanol and water with various Km (Span 20/ethanol, w/w) ratios are depicted in
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Figure 5-1. AT represents the monophasic area (solubilization capacity) and it tends to
increase as the amount of span to ethanol increases in the formulations (Km: 4:1,
AT: 13.1; Km: 1:1, AT: 23.8; Km: 1:4, AT: 30.4; Km: 1:9, AT: 32.0).
5.3.2. Droplet size and pH measurements
Dynamic light scattering technique measures droplet size through direct
measurement of the droplet diffusion coefficient in a dispersed medium undergoing
Brownian motion then the droplet size is obtained from the Stokes-Einstein equation. In
the selected formulations, surfactant, cosurfactant, and oil form the external phase, while
water (aqueous core) is the internal phase. The existing boundaries between oil and
aqueous core are composed of the polar parts of Span 20, the water and ethanol. The
results for droplet size are depicted in Table 5-1. Mean droplet size was not measurable
for formulation containing 5% water by dynamic light scattering. These formulations
may resemble cosolvent systems. It is possible that when water content in the system is
low, water molecules can stay separate without the forming an aqueous droplets. As the
water content increases to 10%, the average droplet size becomes more than 1 nm. It was
observed that as water content further increased, droplet size of microemulsion increased
also.
Surprisingly, the addition of KI to microemulsions shrinks water droplets. This is
due to the salting-in effect which occurs between inorganic anionic ions such as iodide
ions and water molecules. Thus, anionic ion makes water less polar and makes the
organic components dissolve more readily into internal aqueous clusters.133 A schematic
demonstration of microemulsion with and without KI is shown in Figure 5-3.
It is known that iodide, a member of Hofmeister ion series, tends to increase the
solubility of nonpolar components in aqueous solvent by decreasing the surface tension
between water and organic molecules.134 Thus, the polar region (water content in the core)
diminishes and the existing boundary between polar and non-polar molecules shrinks
consequently, which causes the droplet size to decrease.
The pH values of all selected formulations were physiologically acceptable for
topical uses. It was observed that the pH decreased from 5.20 to 4.82 when the amount of
water increased from 5% to 23% (Table 5-1). However, after the incorporation of KI, pH
values increased slightly from 5.68 to 5.32 (5% to 23% water content), as shown in
Table 5-1.
5.3.3. Viscosity measurements
Viscosity of multi-component systems is a polynomial function which depends on
the concentrations of water, surfactant, cosurfactant, and oil in each formulation.135
Figure 5-4 depicts the dynamic viscosity values obtained for all tested formulations in
the presence and absence of KI as it relates to water contents. The viscosity values for

72

Figure 5-3.

A schematic demonstration for the water interface of microemulsions.

(a) microstructure of microemulsion without KI; (b) microstructure of microemulsion
with KI. The internal domain represents the water content.
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Figure 5-4.

The change of dynamic viscosity as a function of water.

Water is the aqueous phase of microemulsions along the dilution line L20.
Microemulsions without KI loading are labeled as ■; microemulsions with KI loading are
labeled as ●.
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formulations without KI were relatively low and ranged between 9 to 11 cPoise. It was
observed for the aforementioned formulations, viscosity increased as the water content
increased from 5 to 23%. The observed increase in the viscosity with the water content is
dependent upon the increase of the dispersant phase droplet’s volume and the increase in
the frequency of collisions between the water droplets in W/O microemulsion system.136
It was noted that after the addition of KI the viscosity of the formulations
(Figure 5-4) increased slightly (10 to 11 cPoise). The increase of viscosity is not only
due to more densed internal aqueous phase, but also due to the increase in the formation
of aqueous transition clusters where iodide ions cause aqueous phase to become more
hydrophobic and free to move.137
5.3.4. Conductivity measurements
The influence of water content on conductivities of selected formulations is
presented in Figure 5-5. The main graph relates overall ions conductivity of water
content from 0 to 24.5%.
In general, when water molecules are dispersed in an oil phase at a small volume
fraction, droplets are separated from each other and exhibits minimum interactions and
liquid conductivity is low. Further addition of water increases the total number of
aqueous droplets which can increase the formation and deformation dynamics of the
transient clusters (aggregation of water molecules) to increase liquid conductivity. The
cluster formation and deformation process is described in three steps: fusion, mass
transfer and fission.138 Transient clusters have significant influence on increasing the
conductivity. The transient collisions of water droplets provide water channels where ions
hop from one droplet to the other.139 Therefore, a rapid increase in conductivity up to 23%
water content was also observed. This observation is consistent with other researchers
who described similar conductivity behavior in W/O microemulsion systems.140
Remarkably, the addition of KI into the selected formulations enhanced conductivities
more than 50-fold as compared to microemulsions without KI. This observation is
consistent with the quantitative charge fluctuation model where the aqueous channels
created by the transient clusters contain more dissociated ions which are able to facilitate
the overall conductivity tremendously.141
5.3.5. In vitro microemulsion skin permeation studies
Cumulative amounts of iodide that permeated through human skin over 24 hours
for selected formulations are depicted in Figure 5-6. Results indicated that at the end of
24 hours all KI formulations with different water contents (5%, 10%, 15%, 20%, and
23%) had significantly better iodide permeation through skin as compared to the control
sample (KI solution; student paired t-test, P<0.05).
Formulation F exhibited the lowest cumulative amount of iodide that permeated
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Figure 5-5. Conductivity of microemulsion formulations along dilution line L20
versus water content.
Microemulsions without KI loading are labeled as ■; microemulsions with KI loading are
labeled as ●.
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Figure 5-6.

Permeation profiles of KI formulations.

Symbols: (■) control (KI solution); (●) Formulation F (5% water); (×) Formulation G (10%
water); (▼) Formulation H (15% water); (▲) Formulation I (20% water); (♦)
Formulation J (23% water).
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the skin at the end of 24 hours out of the five selected formulations (F to J). It permeated
about 2 times the amount of KI as compared to the solution after 24 hours. On the other
hand, Formulation J was the most effective formulation for iodide permeation study
(about 2.5 times of KI solutions) after 24 hours. Statistically, iodide permeation at the end
of 24 hour for Formulation J (23% water content) was significantly higher (student paired
t test, P<0.05) as compared to Formulation F (5% water content), but had no significant
difference compared to Formulation G (10% water content), H (15% water content), and
I (20% water content) (student paired t test, P>0.05).
Values of steady-state flux and cumulative amounts of iodide that permeated are
listed in Table 5-2. Steady-state flux values (Jss) indicates that selected formulations (F to
J) had a significant better permeation of iodide compared to KI solution. These results
indicate that organic components in microemulsion formulations act as penetration
enhancers. They potentially modify the lipid structure within the stratum corneum and
make it looser and more porous for iodide permeation. Likewise, larger amount of water
in w/o microemulsion could influence iodide permeability to a higher extent since
Formulation J (23% water content) had the highest flux rate 0.266±0.037 mg/cm2/h. In
the presence of water, skin is hydrated and exists in a swollen state, thus more void
spaces within the skin create wider diffusion channels.142 In summary, the permeation
profile of iodide within microemulsion formulations is affected by a combination of
factors including permeation enhancement and skin hydration.
5.3.6. Accelerated microstructure stability testing
Centrifugational forces accelerate physical instability of microemulsions and lead
to turbidity and phase separation.143 Brownian motion maintains droplets’ kinetic energy
which causes irregular movements of small droplets, so it prevents droplet settling.
Additionally low interfacial tension and droplets kinetic energy lead to inhibition of
creaming, sedimentation, flocculation, and coalescence.144
All selected formulations (A-J) in Table 5-1 in the presence and the absence of KI
had no phase separation and clarity change by the end of 30 minutes under high
centrifugational forces (13,000 rpm, 13,793 g) which is a sign of the strong physical
stability of formulations.
Thermal stability testing under 40 oC showed no turbidity by the end of three
weeks, thus lending further support to the physical stability of the microemulsion under
thermal stress.
Chemical stability was performed by exploring the presence of degradation
product iodine. Iodine reacts with starch in the presence of iodide and expresses blueblack color. So we utilized iodide-starch test paper as an indicator to detect the existence
of iodine. A series of iodine solution standards with different concentrations (Figure 5-7)
were prepared at 0.05% (2.5E-2 mg/mL iodine), 0.5% (2.5E-1 mg/mL iodine), 1% (5E-1
mg/mL iodine), and 2% (1 mg/mL iodine). The rational for preparing these four iodine
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Table 5-2.
Cumulative permeated iodide (Q24) and flux at steady-state (Jss)
2
(mg/cm /h) of selected formulations.
Formulation
(0.05 g/mL KI)
Solution
F
G
H
I
J

Figure 5-7.

Cumulative Permeated Iodide
(Q24) (mg/cm2)
2.38±0.66
4.31±0.34
5.00±0.66
5.11±0.29
4.88±0.50
5.35±0.53

Flux at Steady-state
(Jss) (mg/cm2/h)
0.127±0.036
0.228±0.014
0.252±0.038
0.254±0.014
0.245±0.029
0.266±0.037

Test papers for sample stability test.

From left to right: sample at 0 week, sample at 2 weeks, sample at 4 weeks, sample with
2.5E-5 g/mL iodine, sample with 2.5E-4 g/mL iodine, sample with 5E-4 g/mL iodine, and
sample with 1E-3 g/mL iodine.
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standards was related to the assumption that if the percentages of degradation of the
initial concentration of potassium iodide in microemulsion (50 mg/mL) were 0.05%,
0.5%, 1% and 2% then the concentrations of iodine that should be formed will be 2.5E-2,
2.5E-1, 5E-1 and 1 mg/mL respectively.
We observed that with increasing iodine concentration the blue-black color
became more intense. Samples were collected over 1 month period (Figure 5-7). At the
end of one month, the absence of blue-dark color in iodide-starch test paper indicates the
percentage of degradation product iodine is much less than 0.5%. Thus, we report with
confidence that KI microemulsion with 23% water is chemically stable for at least one
month.
5.4.

Discussion

Since, the dose requirement for iodide is 150 micrograms per day, a transdermal
delivery of microemulsion iodide is feasible. In this study, we explored a W/O
microemulsion as a vehicle which could potentially improve the permeation of iodide ion
through skin. In this system, Capryol 90®, Span 20, ethanol, and water were combined at
appropriate ratios. Despite the fact that other surfactants with poly-oxyethylene groups
have better solubilization capacity than Span 20, these types of surfactants are not
selected since the residues of peroxide originated from poly-oxyethylene groups may lead
to the oxidation of iodide. Thus to stabilize the microemulsion, a co-surfactant is
necessary to further decrease the interfacial tension between the oil phase and the
aqueous phase. We have selected ethanol as the cosurfactant for this system since it is
relatively polar and miscible with water and considered safe at a major content of less
than 40% w/w. The addition of potassium iodide did not show any evidence of
microemulsion destabilization. Iodide ion disrupts water-water interactions and makes
water more hydrophobic thus forcing water dissolve more organic components including
ethanol, Span 20, and Capryol 90® into the aqueous phase. As a result, the internal
droplet size of water decreases. This phenomenon was also explained by other authors
who illustrated that iodide ions adsorb and interact to the inter-phase.133 On the other
hand, cationic ions such as potassium have subtle effect on microemulsion system.
A perspective application for this iodide microemulsion is envisioned to be in the
therapy for specialized patients who suffer from iodide deficiency or who suffer from
short bowel syndrome where oral absorption is limited. Currently patients with this
illness can only rely on parental routes since the majority of nutritional elements
including iodide may be difficult to get absorbed by GI tract. Therefore, a satisfactory
transdermal delivery system may provide a new advent for the therapy of this disease.
Transdermal delivery of iodide could serve as the first front for the transdermal delivery
of nutrients. Although microemulsion is a non-toxic and non-invasive colloidal
formulation, there are still limitations for topical use because of the poor adherence on
the skin. A patch system of microemulsion will provide the solution for this problem.
Such a patch will maintain the microemulsion entrapped behind the adhesive layer and
the membrane and will control the release of the ions.
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5.5.

Conclusion

In summary, several w/o microemulsion formulations were prepared and fully
characterized and evaluated. The physicochemical characterizations included: pH, droplet
size, viscosity, conductivity, and stability. These studies indicated that the selected
formulations were stable and compatible with iodide ions. The permeation studies in
human skin showed that microemulsion enables the iodide ions to diffuse through the
skin. Further development of this work will be to incorporate the microemulsions into a
patch which can be applied more conveniently in clinical treatment.
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